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ABSTRACT 
 
This study investigated the effects of nonsteroidal anti-inflammatory drugs on 
cockatiels experimentally inoculated with Parrot bornavirus-2 (PaBV-2). Twenty-seven 
cockatiels were randomized into 3 groups of 9 birds each taking into consideration historical 
PaBV shedding, weight, and sex.  Cockatiels were then inoculated with cell culture derived 
PaBV-2 by the intranasal and intramuscular routes.  At 23 days post-inoculation, each group 
received either oral treatment once daily with celecoxib (10.0 mg/kg), meloxicam (1.0 
mg/kg) or placebo. Within 33-79 days post-inoculation; 2 birds were found dead and 6 birds 
were euthanized based on neurological or gastrointestinal signs consistent with 
proventricular dilatation disease. At day 173±2 post-inoculation, the remaining birds (21) 
were euthanized. Necropsy and histopathology results showed lesions characteristic of 
proventricular dilatation disease in most of the cockatiels; there was no statistical difference 
in the nature or severity of lesions between the 3 treatment groups. There was no statistical 
difference between the 3 treatment groups in the detection of PaBV mRNA and PaBV N-
protein using RT-PCR and immunohistochemistry, respectively.  Two birds from the 
meloxicam and 2 birds from the celecoxib groups had black intestinal contents consistent 
with intestinal bleeding. These findings suggest that the use of meloxicam or celecoxib does 
not alter the clinical presentation, viral shedding, gross lesions, histopathology, or viral 
distribution in cockatiels experimentally inoculated with PaBV-2. 
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NOMENCLATURE 
 
NSAIDs Nonsteroidal anti-inflammatory drugs 
PaBV Parrot bornavirus 
BCS Body condition score 
IHC Immunohistochemistry 
RT-PCR Reverse transcriptase polymerase chain reaction  
N-protein                     Nucleocapsid protein  
BoDV                          Borna disease virus 
P                                  Phosphprotein 
M                                 Matrix protein 
PDD                            Proventricular dilatation disease 
FBS                             Fetal bovine serum  
DMEM                        Dulbecco’s modified eagle medium  
DEF                             Duck embryo fibroblast  
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CHAPTER I  
INTRODUCTION  
 
Parrot bornaviruses 1-7 (PaBV - 1-7) are associated with Proventriculur 
dilatation disease (PDD), a progressive fatal neurologic syndrome.
1,2,3
 Proventricular 
dilatation disease is primarily a disease of captive birds of the Psittacidae and 
Cacatuidae families, such as cockatoos, cockatiels, lovebirds, parakeets, conures, 
macaws and parrots, but has been identified in over 80 avian species.
4,5,6,
 Proventricular 
dilatation disease is characterized by infection of the central and peripheral nervous 
system and other organs with PaBV, leading to lymphocytic, plasmacytic infiltration of 
those tissues, and culminating in nervous disorders and gastrointestinal malfunctions. 
6-11
 
Based on clinical and pathological signs of PDD, it has been suggested that the 
disease may result from local inflammatory reactions to the virus within the nerves and 
other tissues.
9,12
 It has therefore been asserted that administration of nonsteroidal anti-
inflammatory drugs (NSAIDs) to birds infected with PaBV may reduce the occurrence 
and severity of the clinical signs and pathological changes due to the virus. 
6,13
 Celecoxib 
and meloxicam are among the NSAIDs purported to be effective and commonly used by 
clinicians in the symptomatic treatment of birds diagnosed with PDD.
14-19
 However, few 
studies have examined the use of NSAIDs 
13,14,16
and none have compared the effects of 
celecoxib and meloxicam in birds infected with PaBV. 
Parrot bornavirus administered to cockatiels disseminates into many tissues and 
causes PDD-like clinical signs, shedding of the virus, and gross pathological and 
 2 
 
histological changes.
10,11,13,20,21
 Cockatiels are an acceptable experimental model in 
studying PDD caused by PaBV. 
10,11,13,20-24
 
The objective of this study was to evaluate differences in the clinical signs, viral 
shedding, and pathology of cockatiels inoculated with PaBV-2 and then treated with 
either celecoxib, meloxicam, or a placebo. We hypothesized that NSAIDs administered 
would reduce pathological effects and therefore clinical signs in PaBV-2 inoculated 
cockatiels.  
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CHAPTER II 
REVIEW OF LITERATURE 
 
Psittaciform 1 Bornavirus 
 Psittaciform 1 bornavirus, a member of the family Bornaviridae, is an 
enveloped, non-segmented negative strand RNA virus.  Psittaciform 1 bornavirus, which 
contains parrot bornaviruses 1-7 (PaBV 1-7) was formerly referred to as avian 
bornavirus, but recent genomic and protein sequencing and phylogenetic analysis of the 
Bornaviridae family have resulted in renaming and taxonomic reorganization.
25
 The new 
nomenclature and taxonomic organization of Bornaviridae includes the genus 
Bornavirus with five species: Mammalian 1 bornavirus, Psittaciform 1 bornavirus, 
Passeriform 1 bornavirus, Passeriform 2 bornavirus, and Waterbird 1 bornavirus.
25 
Bornaviridae, along with Filoviridae, Nyamiviridae, Paramyxoviridae, and 
Rhabdoviridae, belong to the order Monoegavirales. However unlike the other families 
in that order that replicate in the cytoplasm, viruses within Bornaviridae employ 
intranuclear transcription and replication.
26
  Bornaviridae uses a number of strategies 
including alternative RNA splicing, overlapping of transcription units and transcriptional 
signals, read-through of transcriptional initiation sites, and differential use of 
translational initiation codons.
27,28,29
  For example, Bornaviridae employs a unique 
genome replication strategy that involves trimming of triphosphates from the 5’terminal 
of the viral RNA to avoid activation of the innate immune response receptors.
29,30
  The 
bornavirus genome encodes six proteins; nucleocapsid (N), X protein (X), phosphprotein 
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(P), matrix (M), enveloped glycoprotein (G), and the RNA- dependent RNA polymerase 
(L) similar to the other members of the Mononegavirales order. 
31,32
 
Prior to discovery of bornaviruses in birds, Mammalian 1 bornavirus, which 
contains Borna disease viruses (BoDV), was the only species in Bornaviridae. In 2008, 
novel avian viral strains of Bornaviridae were identified in the brain, proventriculus, and 
adrenal gland of birds with proventricular dilatation disease (PDD).
1,2
 Brain 
homogenates containing the avian viral strains, which were identified as PaBV, 
inoculated into cockatiels produced clinical and pathological characteristics of PDD.
21
 
Inoculation of Patagonian conures with PaBV isolated from the brain of birds with 
confirmed PDD, resulted in clinical signs, along with gross and histopathologic lesions, 
of PDD. PaBV was then subsequently demonstrated in the brains of the infected birds, 
thus fulfilling Koch’s postulates and proving that PaBV is an etiological agent of PDD.3 
Psittaciform 1 bornavirus infection, which contains PaBV-1, -2, -3, -4, -7, is 
found mainly in parrots and macaws,
1,2,33,34 
but is also found in other psittaciformes. 
35- 41
 
Bornavirus is also found in passerines,
42-45 
geese,
46,47,48
 mute and trumpeter swans,
46
 and 
wild ducks.
49
 Psittaciform 1 bornavirus is neurotropic, but is found in other tissues 
including the kidneys, medullary cords of the adrenal gland, heart, spleen, liver, lungs, 
pancreas, testes and ovaries. 
20,38,50-55
 The mechanism of transmission of PaBV is 
unknown, but a fecal-oral transmission is considered the primary route of 
infection;
12,52,56
 PaBV mRNA is found  uro-fecal droppings, lumen of renal tubules, and 
urine.
56
 PaBV isolated from urine of naturally infected birds is infectious in cell 
 5 
 
culture.
57
 A respiratory component to transmission is proposed as the virus can be 
aerosolized.
6,52
 It is found in feather calami,
58
 choanal swabs,
52
 and air samples collected 
up to 150 inches from an PaBV infected and shedding bird;
6
 however, birds in close 
contact for 4 months with infected birds did not become infected.
23
 Vertical transmission 
is also suggested as a potential route of transmission.
59-63
  
  
Proventricular Dilatation Disease 
Psittaciform 1 bornavirus infects neurons and other tissues, resulting in an 
pathologic response in the infected bird to the virus leading to the development of 
proventricular dilatation disease.
8
  Proventricular dilatation disease was first recognized 
in North America and Europe in late 1970s and was initially described as Macaw 
Wasting Disease or Macaw Fading Syndrome because it was first reported in an 
outbreak involving macaw species.
64,65
 Although the disease is commonly referred to as 
PDD, it has several synonyms including macaw wasting syndrome, proventricular 
dilatation syndrome, neuropathic gastric dilatation of psittaci-forms, myenteric 
ganglioneuritis, proventricular hypertrophys.
37
 Proventricular dilatation disease is 
primarily a disease of birds of the Psittacidae and Cacatuidae families, such as 
cockatoos, cockatiels, lovebirds, parakeet, conures, macaws and parrots, but also occurs 
in other avian species.
2,3,4,5,12,64,65
 Proventricular dilatation disease is characterized by 
inflammation of the central, peripheral, and autonomic nervous systems, affecting two 
major systems: the neurologic and gastrointestinal systems.
5,6,8,9,10,12,36,52,
 The classical 
signs of PDD involve the gastrointestinal tract and include difficulty in swallowing, 
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regurgitation, and presence of undigested food in feces. Radiographic evaluation shows a 
dilated crop, proventriculus, ventriculus and intestines.
6,12
 Upon necropsy, dilation of the 
crop, proventriculus and ventriculus are frequently noted and the thin walled organs can 
spontaneously rupture
. 3,12
 When clinical signs include gastrointestinal dysfunction, 
autonomic nerves innervating the esophagus, crop, proventriculus, ventriculus, and 
duodenum are affected.
2,6,9,12
 Other clinical signs suggestive of proventricular dilatation 
disease are weight loss over a period of weeks to months, abnormal head movements, 
motor deficits, abdominal distention, and impaction of the crop.
5,6,9,12
  Birds affected by 
proventricular dilatation disease may also have signs relating to the central nervous 
system; blindness, ataxia, aggression, as well as possibly feather plucking, and 
seizures.
8,12,66
 Peripheral neuritis, myenteric ganglioneuritis, and encephalitis occur in 
birds with neurological or gastrointestinal tract signs of PDD. Diagnosis of PDD is 
difficult as it is based upon the presence of clinical signs, radiographic findings and 
biopsy; however, definitive diagnosis is by histological findings of lymphocytic 
infiltration of the enteric or central nervous system with corresponding local 
inflammation within nerves and ganglia.
5,10,11,12,20,52,64
 Similar infiltrates may also be 
present in the spinal cord, peripheral nerves, conductive tissue of the heart, smooth and 
cardiac muscle, and adrenal glands.
2,10,11,20
  
 
Nonsteroidal Anti-Inflammatory Drugs 
Presently, there is no proven efficacious treatment for PDD or other Psittaciform 
1 bornavirus infections. Experimentally, INF-α inhibits viral infection and viral load in 
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quail cell culture
30 
and ribavirin inhibits transcription and reduces viral load in DEF 
cells.
67,68
 Symptomatic treatment and supportive care are currently the principal 
therapies for PDD.
5,12
 It is postulated that nonsteroidal anti-inflammatory drugs and 
immunosuppressant drugs can inhibit or reduce the inflammatory reaction of PaBV 
infection and thus will lessen the severity of clinical signs of PDD.
5,12
 Celecoxib and 
meloxicam, both NSAIDs, and cyclosporine, an immunosuppressant, are used clinically 
and experimentally 
13,14,16
 but their use is controversial. In cockatiels experimentally 
infected with PaBV-4 and treated with meloxicam, severe weight loss and depression 
resulted in the birds being euthanized between 60 to 118 days after viral inoculation. 
Gross lesions and histopathology findings were consistent with PDD and blood was 
found in the proventriculus and intestines.
13
 
The principal mechanism of action of nonsteroidal anti-inflammatory drugs is the 
inhibition cyclooxygenase (COX). Cyclooxygenase catalyzes the production of 
prostaglandins from arachidonic acid.
69,70,71
  Cyclooxygenase exists as two main 
isoenzymes, COX-1 and COX-2. COX-1 enzymes are expressed in most tissues and 
produce prostaglandins and thromboxanes involved in homeostatic physiological 
processes.
69,70,71
 COX-1 is considered the constitutive or maintenance form of the 
enzyme, maintaining the integrity of the gastrointestinal mucosa, affecting platelet 
aggregation, influencing renal blood flow and hemodynamics.
70,72,73,74
 COX-2 is the 
inducible form of the enzyme, with a low basal expression level and is induced in 
response to inflammatory stimulus, such as lipopolysaccharides, cytokines, and 
injury.
69,70,71,73
 Traditional NSAIDs that inhibit both COX-1 and COX-2 are known as 
 8 
 
non-selective NSAIDs. With the discovery of COX-2 in the 1990s, selective COX-2 
inhibitors were developed to provide anti-inflammatory and analgesic properties without 
inhibiting the protective mechanisms of COX-1. COX-2 selective inhibitors provide 
anti-inflammatory and analgesic effects without altering the homeostatic functions of 
COX-1. Thus the selective COX-2 inhibitors can have fewer toxic effects, such as the 
gastrointestinal and renal toxicities, than those of the non-selective, traditional NSAIDs.  
The toxic effects and pharmacokinetics of NSAIDs such as meloxicam, flunixin 
meglumine, carprofen, ketoprofen and diclofenac, have been evaluated in birds including 
bobwhite quail (Colinus virginianus),
75
 Gyps vultures ,
76-80 
budgerigars (Melopsittacus 
undulates),
81,82
 pigeons (Columba livia),
83-86
 Japanese quail (Coturnix japonica),
84,87
  
African grey parrots (Psittacus erithacus),
88,89
 cockatiels (Nymphicus hollandicus),
90
 
American kestrels (Falco sparverius),
91
 Patagonian conures (Cyanoliseus patagonus),
82
 
mynah (Leucopsar rothschildi),
 84
 Hispaniolan amazon parrots (Amazona ventralis),
94,95
 
and red-tailed hawks (Buteo jamaicensis),
96
 domestic fowl,
97,83,84,92,93
 and great horned 
owls (Bubo virginianus).
96 
 Possible adverse effects of NSAIDs are a decrease in the 
secretion of uric acid and ischemia in the kidneys from renal arterial vasoconstriction. 
NSAID toxicity will be exhibited histopathologically as mild glomerular lesions, renal 
tubular cell necrosis, gastric ulcers, and/or hepatic lipidosis.  Renal and hepatic lesions 
have been reported in broiler chicks, pigeons, Japanese quail, and mynah birds when 
administrating diclofenac.
84
 Renal lesions are a particular issue in Asian vultures (Gyps 
bengalensis, Gyps indicus, and Gyps tenuirostris) when administering diclofenac.
76,80
 
Renal lesions have been also seen in budgerigar treated with flunixin meglumine.
81
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However, the evaluation of meloxicam in budgerigars,
81 
African grey parrots, 
89
 
Hispaniolan amazon parrots,
95
 domestic pigeons,
86
 Japanese quail
87
 and Asian vultures
78
 
have found no significant renal, gastrointestinal of hepatic adverse effects. NSAID 
metabolism, pharmacokinetics and toxicity appear to depend on avian species, NSAID 
utilized, and route of administration. 
Meloxicam and celecoxib are frequently prescribed NSAIDs by veterinarians for 
companion birds.
14,16
 Celecoxib (Celebrex®), a coxib class of NSAID, was the first 
COX-2 selective inhibitor introduced for the treatment of humans with active 
osteoarthritis, ankylosing spondylitis or rheumatoid arthritis in 1998.
72 
Meloxicam is a 
member of the enolic class of NSAIDs, which is also a COX-2 selective inhibitor used 
for it analgesic, anti-inflammatory, and antipyretic properties. Celecoxib selectivity for 
COX-2 is believed to be 30-fold more than for COX-1,  and meloxicam is believed to 
have an 18-fold greater selectivity for COX-2 than for COX-1.
98
  
 
Experimental Models  
Experimentally infection of birds with PaBV has confirmed the virus’s 
etiological role in the development of PDD.
3,10,11,20,21
 PDD can be experimentally 
induced in healthy birds by inoculation of PaBV infected-brain tissue
21
 or PaBV 
obtained from cell culture.
3,10,11,20 
Gray et al. infected Patagonian conures with PaBV, 
grown in DEF cell culture, by intramuscular injection; the birds developed clinical signs, 
gross abnormalities, and histological lesions consistent with PDD within 66 days post-
inoculation.
3
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A cockatiel model is routinely used for the investigation of PaBV infections and 
PDD.
10,11,13,20-24,62
 Gancz et al. first demonstrated that clinical and pathological changes 
characteristic of PDD could be induced in cockatiels using intramuscular, intraocular, 
intranasal, and oral inoculation with PaBV positive brain homogenate from birds with 
PDD. Clinical signs, gross changes, and histopathological lesions consistent with PDD 
were found within 60-95 days post-inoculation.
21
 
Virus isolated from infected birds and grown in DEF cell culture can also cause 
infection and PDD-like lesions when inoculated into cockatiels.
10
 Cockatiels inoculated 
by the oral and intramuscular route developed clinical signs and histopathological 
lesions of PDD 30-45 days post-inoculation.
10 
Payne et al. showed unusually severe 
gross and histopathology lesions in cockatiels 92 and 110 days post-inoculation.
20
 
Hoppes et al. used DEF cell culture derived PaBV-4 to evaluate the use of meloxicam in 
experimentally induce PDD; challenged birds developed PDD-like lesions.
12
 
The growth of infectious PaBV is not restricted to DEF cells. Piepenbring et al. 
infected cockatiels by the intracerebral and intravenous routes with PaBV-4 grown in a 
quail cell line; birds develop clinical signs, gross necropsy findings, and 
histopathological changes characteristic of PDD.
11
 Rubbenstroth et al. inoculated 
cockatiels by a combination of intramuscular, subcutaneous, and oral routes with PaBV-
4 grown and isolated from quail fibroblast cells. PaBV-4 inoculated cockatiels showed 
clinical signs of PDD within 24 weeks post-inoculation.
23
 
These studies confirm cockatiels are an accepted experimental model for PDD 
research, since PaBV isolated directly from the brain of infected birds or grown in cell 
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culture is inoculated by the intramuscular, oral, subcutaneous, intracerebral or 
intravenous route results in clinical signs, gross lesions, and histological changes 
characteristic of PDD. 
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CHAPTER III 
MATERIALS AND METHODS 
 
Parrot Bornavirus  
Virus was obtained from a supply cultured and isolated from the brain of 
experimentally infected cockatiels’ (Nymphicus hollandicus) that developed PDD.10 
Virus for inoculation was grown as previously described.
99
 Briefly, duck embryo 
fibroblast (DEF) cell cultures were inoculated with an aliquot of stock virus and 
maintained in Dulbecco’s modified eagle medium (DMEM) (Gibco®, Life Technologies 
Co) with 10% fetal bovine serum (FBS) (Gibco®, Life Technologies Co) at 37°C in an 
atmosphere of 5% CO2. After 3 days of incubation, DEF cells were harvested three times 
by divided into 1.0mL of stock virus aliquots, and stored at -80°C. Virus was confirmed 
as PaBV-2 by RNA extraction and RT-PCR analysis followed by sequence analysis of 
the PCR product.
99
  
Birds were inoculated by intranasal and intramuscular administration with DEF 
cells containing 8 X 10
4
 focus forming units (FFU) of PaBV-2. A similar method is 
effective in inducing proventricular dilatation disease in cockatiels.
10,13
 
 
Nonsteroidal Anti-Inflammatory Drugs 
Meloxicam, 15mg tablets, was used (Lupin, Pharmaceuticals, Inc. Baltimore, 
MD, USA) A meloxicam liquid suspension, 1.0 mg/mL, was made by crushing 3 tablets, 
using a mortar and pestle, dissolving in 1.0mL deionized water, adding 10.0 mL of Ora-
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Plus (Perrigro® Co., Dublin, Ireland) suspending vehicle, and adding Ora-Sweet 
(Perrigro® Co., Dublin, Ireland) to obtain a final volume of 45.0 mL. 
Celecoxib, 50.0 mg capsules, was used (Pfizer Inc., Mission, KS, USA). A 
celecoxib liquid suspension, 10.0 mg/mL, was made by combining 9 capsules with 
1.0mL deionized water and 10.0 mL of Ora-Plus suspending vehicle, and adding Ora-
Sweet to obtain a final volume of 45.0mL. 
Nonsteroidal anti-inflammatory drugs for this study were compounded in the 
laboratory from commercially available formulations to facilitate drug delivery to study 
subjects. All solutions were stored at 4ºC and recompounded every 30 days. Prior to 
administration, drug solutions and control solution were warmed to room temperature. 
 
Animals 
Twenty-seven male and female cockatiels (Nymphicus hollandicus), ranging in 
weight from 79 to 145 g, mean of 101 g were used. The birds were assessed as healthy 
based on physical examination and medical history. The cockatiels were quarantined for 
60 days, during which time each bird was tested thrice for Parrot bornavirus (PaBV), 
psittacid herpesvirus (genotype1-4), Chlamydophila spp and Macrorhabdus 
ornithogaster (avian gastric yeast) via cloacal swab. The cockatiels were housed in flight 
cages, 14 or 13 birds per cage, at the Schubot Exotic Bird Health Center. Birds were fed 
a 1/6 cup per bird of premium daily FruitBlend with natural fruit flavors (ZuPreem®, 
Shawnee, KS, USA) bird food, and had access to water ad libitum. This research study 
was approved by the Texas A&M University Office of Research Compliance. 
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Experimental Protocol 
 The procedure protocol timeline is illustrated in Figure 1. Approximately, one 
month prior to beginning experimental inoculation, birds were randomized, matched 
with respect to historical shedding, weight and sex, into three groups of nine birds each: 
Group1 - experimentally inoculated and then 23 days following inoculation, treated 
orally, once daily with the delivery solution  (water, Ora-plus, and Ora-Sweet) without 
any NSAID; Group 2 - experimentally inoculated and then 23 days following 
inoculation, treated orally, once daily with 1.0 mg/kg meloxicam; and, Group 3 - 
experimentally inoculated and then 23 days following inoculation, treated orally, once 
daily with 10.0 mg/kg celecoxib. Treatments were done prior to morning feeding. Drug 
treatment of each group was kept blinded to the person treating and assessing the birds 
until study completion; this was a randomized placebo-controlled blinded study. 
Birds were observed daily for any abnormal clinical signs and deviations from 
normal behavior; including feather fluffing, bowed head, lack of vocalization, almond 
shape eye, over eating, lethargy, and staying on bottom of cage. Cloacal swabs were 
collected twice and the weights and body condition scores (BCS) assessed once before 
inoculation. After viral inoculation, birds were weighed and BCS was assessed weekly; 
cloacal swabs were collected every third week and stored at -80ºC until assayed by RT-
PCR. 
Body condition scores were determined by assessing the shape of the keel and 
pectoral muscle. Body condition scores ranged from 1 to 5, lowest to highest score, 
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respectively. Criteria for determining BCS was adapted from Heatley et al. and is 
described in Table 1.
100
 
A bird was withdrawn from the study and euthanized if it met the following pre-
established criteria: weight loss >20% of initial weight; BCS of 1, and/or, 
recommendation by attending veterinarian. The procedure for euthanasia, sample 
collection, and necropsy was as described for birds that completed the treatment period.  
On day 173 (±2) following experimental inoculation and day 150 (±2) of NSAID 
or placebo treatment, birds were euthanized: Birds were anesthetized with 5% isoflurane 
followed by 100% carbon dioxide. Prior to euthanasia, weight, BCS, urine, cloacal swab, 
and blood were collected. Urine was collected as previously described by Heatley et al.
56 
 
Immediately following death, a complete necropsy was performed and gross lesions 
were recorded and photographed. Samples, 2 per organ, of heart, liver, feather follicle, 
spleen, crop, proventriculus, ventriculus, intestine, gonad, pancreas, adrenal gland, 
kidney, lung, spinal cord, brain, eye, aqueous humor, optic nerve, brachial plexus, and 
sciatic nerve were collected and stored at -80ºC freezer for later analyses by RT-PCR. 
The remainders of the organs were placed in 10% buffered formalin for histopathology 
and immunohistochemistry (IHC) testing. 
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Figure 1. Experimental timeline of cockatiels inoculated with PaBV-2 and treated with placebo, meloxicam, or 
celecoxib.                                                                                   
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Table 1. Criteria for body condition score used on cockatiels experimentally 
inoculated with PaBV-2 and treated with placebo, meloxicam, or celecoxib. In the 
schematic representations, the bird is in a ventrodorsal orientation. The keel is illustrated 
in black and pectoral muscles are illustrated in red. Adapted from Heatley et al.
100
 
BCS Criteria Schematic representation 
 
1 
 
 pectoral muscles are concave around the keel 
 
 
2 
 
pectoral muscles forms a flat silhouette line 
around the keel 
 
 
3 
 
pectoral muscles are convex around the keel 
(ellipse) 
 
 
4 
 
pectoral muscles form a semi-circular aver 
and around  the keel  (1/2 circle) 
 
 
5 
 
pectoral muscles extend beyond the keel bone 
(Mcdonald’s M) 
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Detection of PaBV mRNA by RT-PCR 
Tissue, urine, and cloacal swabs were analyzed by TaqMan-based one-step 
reverse transcriptase real-time PCR (TaqMan® Fast Virus 1-Step, Life Technologies 
Co.). Total viral RNA was isolated from each sample using the QIAamp viral RNA mini 
kit (Qiagen, Valencia, Ca). Purified RNA was eluted in 60.0 uL elution buffer and stored 
at -80°C until use. PaBV phosphoprotein (P) gene mRNA was detected using Taqman 
RT-PCR assay performed with TaqMan® Fast Virus 1-Step Master Mix 
(Invitrogen,Carlsbad, Ca) and PaBV  P primers 
(5’AAGAAGAA[Y]CC[Y]TCCATGATCTC 3’ and 5’-
AA[Y]TGCCGAAT[B]A[R]GTCATC- 3’) and Taqman probe (5’-FAM-
TCGATAACTG [Y]TCCCTTCCGGTC-BHQ-3’).  PaBV matrix (M) gene mRNA 
was detected using PaBV M primers (5'- GGTAATTGTTCCTGGATGG-3') and 
(5'-ACACCAATGTTCCGAAGACG-3'), and Taqman probe. (5’-FAM-
TCGATAACTG [Y]TCCCTTCCGGTC-BHQ-3’). Each reaction was carried out using 
6.0 µL of Taqman fast virus master mix, 5.0 µL of mRNA of sample, 0.4µL ultrapure 
H2O, 0.3 µM primers and 0.3 µM probe in a 12.0 µL final reaction volume. All reactions 
were carried out using: initial denaturing for 5 minutes at 48ºC and 20 seconds at 95ºC, 
then 45 amplification cycling parameters, and then reverse transcriptase inactivation and 
polymerase activation for 3 seconds at 95ºC and 30 seconds at 56ºC. Results were 
analyzed using the Sequence Detection System, Version 2.4.1 (SDS 2.4) software (Life 
Technologies Co.). All samples were tested in duplicate for both the M and P gene. 
Samples were considered negative when cycle threshold (CT) ≥37.0. If a sample was 
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positive for the M gene and negative for the P gene or vice versa, samples were retested 
with the Taqman RT-PCR assay. 
 
Immunohistochemistry 
 Immunohistochemistry was performed on tissues obtained at necropsy. The assay 
was performed according to previously described methods.
42
 Presence of viral protein 
and assignment of a semi-quantified category the pathologist as: none detected, mild 
amount detected, moderated amount detected, severe amount detected. 
 
Statistical Analysis 
The Gehan-Breslow method was used to analyze differences in survival between 
the treatment groups. Two Way Repeated Measures Analysis of Variance (ANOVA) 
was used to compare weight changes between the treatment groups and day over the 
experimental time course. The Kruskal-Wallis One Way ANOVA on Ranks was used to 
ascertain differences in histological and immunohistochemistry findings. A P ≤ 0.05 was 
considered statistically significant. SigmaPlot version 10.0.1 was used for performing all 
statistical analyses (Systat Software, Inc., San Jose, CA). 
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CHAPTER IV 
RESULTS 
 
Clinical Observations 
No significant difference in survival rate occurred between the 3 treatment 
groups (Figure 2). In the control group, 2 of 9 birds were euthanized prior to the end of 
the study; birds number’s 237 and 302 were euthanized on day 54 and 61 after 
inoculation (day 31 and 38 of treatment), respectively. In the meloxicam treatment 
group, 2 of 9 birds were euthanized or found dead prior to the end of the study; birds 
number’s 10 and 2725 were euthanized or found dead on day 33 and 79 after inculation 
(day 10 and 56 of treatment), respectively. In the celecoxib treatment group, 4 of 9 birds 
were euthanized or found prior to the end of the study; birds number’s 204, 2441, 241, 
and 196 were euthanized or found dead on day 37, 43, 45, and 74 after inoculation (day 
14, 20, 22, and 51 of treatment), respectively. Of these 8 birds, two were found dead and 
the remaining 6 showed neurological or gastrointestinal signs characteristic to PDD 
(Table 2).  
No significant differences in weight occurred between the groups over the study 
period within each treatment group, the weights at the end of the study, day 173 ±2 post-
inoculation was not significantly different from the weight prior to inoculation nor prior 
to treatment (Figure 3). Within each treatment group, weight varied significantly based 
on day. In the control group, the weight on day -31 and 55 after inoculation was 
significantly different, 99.0 and 89.7 grams, respectively. In the meloxicam treated 
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group, the weights on days 26, 33, 41, 48, 55, 63, and 69 were significantly less than on 
day -31 after inoculation, 94.2, 87.0, 88.9, 88.6, 89.4, 92.2, 93.0 and 102.9 grams, 
respectively. In the celecoxib treated group, the weights on days 33, 41, 48, 55, 63, 69, 
and 76 were significantly less than on day -31 after inoculation, 87.9, 89.8, 90.7, 89.6, 
91.5, 91.6, 91.2, and 102.6 grams, respectively.  
 BCS did not differ significantly based on treatment group or day over the study 
period (Figure 4). 
 However, birds that were euthanized early from the treatment trial, tended to 
have lost weight and BCS over the course of the study. An exception was bird number 
2725 from the meloxicam group, that at the time of euthanasia had a greatly increased 
weight compared to other birds at that time period but had a low BCS; at necropsy this 
bird had a profoundly dilated crop and a dilated proventriculus that were full of feed 
(Figure 5B). This accumulated seed may have contributed to the observed increase in 
weight. 
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Figure 2. Survival analysis of cockatiels inoculated with PaBV-2 and treated with 
placebo, meloxicam, or celecoxib. The Gehan-Breslow statistic for survival curve was 
used to generate the survival analysis. Birds were experimentally inoculated with PaBV-
2 on day 0. On day 23 post-inoculation (dashed arrow), birds were treated orally, once 
daily with the following: placebo control group (solid black line), meloxicam (dotted 
grey line) and celecoxib (dashed grey line). 
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Treatment Bird ID Euthanized day BCS
Weights 
(gms)
237 54 3 95
302 61 2 74.8
10 33 1 76
2725 79 2 117.6
204 37 2 97
2441 43 2 74.5
241 45 3 83
196 74 1 64
Observations
Loss of balance and flying into cage wall
Regurgitating with a distended crop
 Found dead
Regurgitation, enlarged crops, feather fluffing, head drooping and tilted, off 
balanced, lethargic, spends most of the time on the cage floor
Found dead 
Eyes closed, unstable, head tilt, lethargic. 
Eyes closed, unstable, head tilt, lethargic
Enlarged crop, eyes closed, unstable, head tilt, lethargic, feces dark in color
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Table 2.  Cockatiels experimentally inoculated with PaBV-2 and treated with placebo, meloxicam, or celecoxib which 
were removed early from treatment study. Eight of the 27 birds were euthanized or died prior to the end of the study. BCS 
and weights were collected prior to necropsy.
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Figure 3. Mean weights of cockatiels inoculated with PaBV-2 and treated with 
placebo, meloxicam, or celecoxib. Birds were experimentally inoculated with PaBV-2 
on day 0. On day 23 post-inoculation (solid arrow), birds were treated orally, once daily 
with the following: placebo control group (green triangle, solid black line), meloxicam 
(blue circle, dotted black line) and celecoxib (red square, dashed black line) The final 
weight of the birds terminated early is represented by green triangles (control), blue 
circles (meloxicam), or red squares (celecoxib). 
a
For control group, weight significantly 
different from weight at day -33 post-inoculation . 
b
For meloxicam treated group, weight 
significantly different from weight at day -33 post-inoculation. 
c
For celecoxib treated 
group, weight significantly different from weight at day -33 post-inoculation. 
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Figure 4. Mean body condition score of cockatiels inoculated with PaBV-2 and 
treated with placebo, meloxicam, or celecoxib. Birds were experimentally inoculated 
with PaBV-2 on day 0. On day 23 post-inoculation (solid arrow), birds were treated 
orally, once daily with the following: placebo control group – (green triangle, solid black 
line), meloxicam (blue circle, dotted black line) and celecoxib (red square, dashed black 
line). Final body condition score of birds that died or were removed early are represented 
by green triangles (control), blue circles (meloxicam), or red squares (celecoxib).  
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Figure 5.  Gross findings at necropsy of cockatiels inoculated with PaBV-2 and 
treated with placebo, meloxicam, or celecoxib. 
A. Bird number 302 control group, euthanized on day 61 post-inoculation. Severe 
dilation of proventiculus (yellow arrow) and crop (red arrow) 
B. Bird number 2725 meloxicam group, euthanized on day 79 post-inoculation. Severe 
dilation of proventiculus (yellow arrow) and crop (red arrow) 
C. Bird number 210 meloxicam group, euthanized on day 173 post-inoculation.  
Moderate dilation of proventiculus (yellow arrow) 
D. Bird number2441 celecoxib group, euthanized on day 43 post-inoculation. Moderate 
dilation of proventiculus (yellow arrow) 
E. Bird number 241 celecoxib group, euthanized on day 45 post-inoculation. Mild 
dilation of proventiculus (yellow arrow) with undigested seed present in the intestines 
(white arrow).  
F. Bird number 196 celecoxib group, euthanized on day 74 post-inoculation. Mild 
dilation of proventiculus (yellow arrow), severe dilation of crop (red arrow) and blacken 
intestinal content (white arrow) 
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Detection of PaBV mRNA on Cloacal Swabs 
Prior to experimental inoculation, cloacal swab testing for viral mRNA were 
negative for all birds, with the exception of one; bird number 221 had a positive cloacal 
swab on day -17 of inoculation; however, this bird’s was negative on days -31, 13, and 
20 post-inoculation (Table 3). PaBV shedding was first detected 42 days post-
inoculation in the meloxicam and celecoxib groups. At the termination of the study (173 
± 2 days), all birds that were not removed early from the study had positive cloacal 
swabs, with the exception of bird number 261 in the meloxicam group. The cumulative 
numbers of birds with positive cloacal swabs by the end of the study were 8 of 9, 6 of 9, 
and 7 of 9 in the control, meloxicam, and celecoxib groups, respectively.   
 
Necropsy and Histopathology 
Gross abnormalities at necropsy were dilated crop, dilated proventriculus and 
dilated heart.  However these abnormalities were not consistently present nor of 
consistent severity (Table 4 and Figure 5).  Birds that were removed or died early had 
more pronounced crop and proventiculus dilatation than birds that survived until day 
173±2 post-inoculation. Gross abnormalities were less commonly noted in the air sacs, 
intestines, pancreas, kidneys, liver and spleen (APPENDIX B). Additionally, black 
intestinal contents were present in 2 birds of meloxicam and 2 birds of celecoxib group. 
These four birds numbers, 10 and 2725 in the meloxicam and 196 and 204 in the 
celebrex group were euthanized early in the study. 
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Histopathological changes were noted in a variety of tissues but were not 
significantly different between the three groups (Table 5). The lesions observed included 
lymphoplasmacytic myenteric ganglioneuritis in the crop, proventriculus, ventriculus 
and intestines; lymph nodules scattered, multifocal dilution of tubules/ interstitial 
inflammation, fibrosis and/or mineralization in the kidney; lymphoplasmacytic 
infiltration within the epicardial, myocardial, and/or Purkinje cells of the heart; 
lymphoplasmacytic perivascular cuffing in the central nervous system. 
Histolopathological changes were seen in the, liver, pancreas, lung, spleen, optic nerve 
and adrenals but in lesser frequency (APPENDIX C).  
 
Immunohistochemistry  
There was no significant difference in the viral distribution or amount between 
the three groups and tissues. The virus was predominantly detected in the brain, heart, 
gastrointestinal tract and kidneys (Table 6). A lower prevalence of virus was also 
detected in liver, pancreas, lung, spleen, adrenal optic nerve, uropygial gland, cloaca, 
gonads, and skin/ feather follicles (APPENDIX C). Skeletal muscle was the only tissue 
consistently negative for the virus. Virus was not detected in any tissues of 4 birds, 1, 2, 
and 1 in the control, meloxicam, and celecoxib, respectively.  
 
Detection of Viral mRNA in Necropsy 
There was no significant difference in the detection of viral mRNA between 
groups. Viral mRNA was detected in midbrain, hindbrain, cerebellum, forebrain, kidney, 
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urine and cloacal swab (Table 7). In the control and meloxicam group, no viral mRNA 
could be detected in 1 and 2 birds, respectably. In the celecoxib group, no viral mRNA 
could be detected in the kidney of two birds (numbers 204 and 2441), but was detected 
in the brain. However in bird number 2441, viral mRNA was detected in the urine 
sample. Birds with negative cloacal swab results, except bird number 261 from the 
meloxicam group, were removed from the study early.  
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Treatment Bird ID -31 -17 13 20 33 37 42 43 45 54 61 63 74 79 84 103 125 146 173±2
*237 - - - - N N - N N - N N N N N N N N N
*302 - - - - N N - N N N + N N N N N N N N
236 - - - - N N - N N N N - N N + + + + +
239 - - - - N N - N N N N + N N + + + + +
791 - - - - N N - N N N N + N N + + + + +
9491 - - - - N N - N N N N + N N + + + + +
92 - - - - N N - N N N N + N N + + + + +
2820 - - - - N N - N N N N + N N + + + - +
1460 - - - - N N - N N N N - N N + + + + +
*10 - - - - - N N N N N N N N N N N N N N
*2725 - - - - N N - N N N N - N - N N N N N
1662 - - - - N N - N N N N + N N + + + + +
254 - - - - N N - N N N N - N N + + + + +
691 - - - - N N - N N N N + N N + + + + +
210 - - - - N N - N N N N - N N - - + - +
229 - - - - N N - N N N N + N N + + + + +
221 - + - - N N + N N N N + N N + + + + +
261 - - - - N N - N N N N - N N - - - - -
*204 - - - - N - N N N N N N N N N N N N N
*2441 - - - - N N - - N N N N N N N N N N N
*241 - - - - N N + N - N N N N N N N N N N
*196 - - - - N N + N N N N - + N N N N N N
265 - - - - N N - N N N N + N N + + + - +
215 - - - - N N + N N N N + N N + + + + +
247 - - - - N N - N N N N - N N + + + + +
297 - - - - N N + N N N N + N N + + + + +
279 - - - - N N - N N N N + N N + + + + +
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Table 3. Detection of viral mRNA in cloaca of cockatiels inoculated with PaBV-2 
and treated with placebo, meloxicam, or celecoxib.  PaBV m-RNA detection in 
cloacal swabs of uro-feces from PaBV-2 inoculated cockatiels. RT-PCR testing 
identified PaBV matrix and phosphoprotein mRNA. (-) negative-cycle thresholds >37.0; 
(+) positive detection for viral mRNA; (N)-no sample collected; (*) euthanized prior to 
the end of treatment. 
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Treatment Bird ID
Heart 
dilatation
Crop 
dilataion
Proventriculus 
dilatation
*237 - - -
*302 - +++ +++
236 + - -
239 - - -
791 + - +
9491 + - +
92 - - -
2820 + - -
1460 + - +
*10 - ++ ++
*2725 - +++ +++
1662 + + +
254 + + +
691 - - -
210 + - ++
229 - + +
221 - + +
261 - - +
*204 - +++ +++
*2441 - - ++
*241 - - +
*196 - +++ +
265 + - -
215 + - +
247 + - +
297 + - -
279 + - +
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Table 4. Gross necropsy results of cockatiels inoculated with PaBV-2 and treated 
with placebo, meloxicam, or celecoxib. For heart: (-) no dilatation; (+) dilatation. For 
crop and proventriculus: (-) no dilatation; (+) mild dilatation; (++) moderate dilatation; 
(+++) severe dilatation. Bird ID proceeded with (*) euthanized prior to the end of 
treatment.  
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Treatment Bird ID Brain Spinal cord Heart Liver Intestine Crop Proventriculus Ventriculus Pancreas Spleen Kidney Lung Optic nerve Adrenal
*237 - + - - - - - - - - + - N N
*302 - - - + + + + + - - + - - N
236 - - + - + + + + + + + + - N
239 + - + - + - + + - + + - - N
791 - - + - + - + + - - + - - N
9491 + + + - - + + + - + + - - +
92 + + + + - + + + - N + + + N
2820 - - + - + - + + - N + - - N
1460 + - + + + + + + + + + - - N- -
*10 - - - + - - + - - - + - - N
*2725 + + + + + + + + - N + + - N
1662 - - - - + + + + - N + + - N
254 - - + + + - + + + - + - - +
691 - - - + - - - - - + + - + +
210 + + + - - - + + - - + + + +
229 - + - + - - + + - - - - - +
221 + + + - + + + + - - + + + +
261 + - - + - - + + - - + - - N- - + + + -
*204 + + + + + + + + N N + - + +
*2441 + - + + + + + + - - + - N N
*241 + + + - + + + + - - + - N N
*196 + + + + + + + + + N + N + N
265 + - + - + - + + - + + - - +
215 - - + + + + + + - + + + - +
247 + - + - + + + + - + + - - N
297 - - + - - - - - - - + - N -
279 - - - + - - - - - + + - N N
0.565 N 0.236 0.343 0.147 0.368 0.538 0.538 N N 0.343 0.754 N N
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Table 5. Histopathological lesions of cockatiels inoculated with PaBV-2 and treated 
with placebo, meloxicam, or celecoxib. Distribution of histopathologic lesions 
attributable to PaBV infection. Presence (+) or absence (-) of lesions. No statistical 
difference between groups. P<0.05, Kruskal-Walli One Way Analysis of Variance on 
Ranks. (N) tissue not examined histopathologically; (*) euthanized prior to the end of 
study. 
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Treatment Bird ID Brain Heart Liver Intestine Crop Proventriculus Ventriculus Pancreas Kidney Lung
*237 - N N N N - N N N N
*302 +++ N N N N - N N N N
236 +++ ++ - +++ ++ +++ +++ +++ ++ +
239 +++ N N ++ ++ +++ +++ +++ ++ N
791 ++ N N ++ ++ ++ ++ N N +
9491 +++ +++ N ++ ++ ++ ++ - + N
92 +++ +++ + ++ ++ ++ ++ + +++ +
2820 + + - ++ ++ +++ +++ +++ ++ +
1460 +++ ++ + +++ + +++ +++ +++ - +
*10 - N N N N - N N N N
*2725 +++ N N N N - N N N N
1662 ++ N - ++ + ++ ++ N N -
254 ++ N - +++ + ++ ++ ++ ++ -
691 +++ ++ ++ ++ + ++ ++ ++ +++ ++
210 +++ N N - - + + - N N
229 +++ N N ++ + ++ ++ - - N
221 +++ ++ ++ ++ + ++ ++ N ++ ++
261 - N N - - - - - N N
*204 + N N N N - N N N N
*2441 - N N N N - N N N N
*241 ++ N N N N - N N N N
*196 +++ N N N N ++ N N N N
265 +++ N - ++ + ++ ++ ++ +++ +
215 ++ N ++ ++ ++ +++ +++ ++ +++ +
247 +++ ++ N ++ ++ +++ +++ ++ ++ ++
297 +++ N N ++ ++ ++ ++ N N ++
279 +++ N ++ ++ + + + ++ +++ N
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Table 6.  IHC detection of PaBV-2 in tissues of cockatiels inoculated with PaBV-2 
and treated with placebo, meloxicam, or celecoxib. Tissue distribution of PaBV-2 N-
protein antigen by IHC. Immunohistochemistry staining scores: (-) no PaBV-2 N-protein 
antigen detection; (+) mild PaBV-2 N-protein antigen detection; (++) moderate PaBV-2 
N-protein antigen detection; (+++) severe PaBV-2 N-protein antigen detection; (N) 
tissue not examined; (*) euthanized prior to the end of treatment. 
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Treatment Bird ID Midbrain Hindbrain Cerebellum Forebrain Kidney Urine Cloacal swab 
*237 - - - - - - -
*302 + + + + + N +
236 + + + + + + +
239 + + + + + + +
791 + + + + + + +
9491 + + + + + + +
92 + + + + + + +
2820 + + + + + + +
1460 + + + + + + +
*10 - - - - - N -
*2725 + + + + + N -
1662 + + + + + + +
254 + + + + + + +
691 + + + + + N +
210 + + + + + N +
229 + + + + + + +
221 + + + + + + +
261 - - - - - - -
*204 + + + + - N -
*2441 - + - + - + -
*241 + + + + + N -
*196 + + + + + N +
265 + + + + + N +
215 + + + + + + +
247 + + + + + + +
297 + + + + + + +
279 + + + + + N +
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Table 7. Viral mRNA detected at necropsy of cockatiels inoculated with PaBV-2 
and treated with placebo, meloxicam, or celecoxib. PaBV matrix and phosphoprotein 
mRNA reverse transcription polymerase chain reaction (RT-PCR) on samples collected 
at necropsy. (-) No viral mRNA detected; (+) viral mRNA detected; (N) sample not 
examined or no sample collected; (*) euthanized prior to the end of treatment. 
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CHAPTER V 
DISCUSSION AND CONCLUSION 
 
Oral administration of meloxicam, 1.0 mg/kg, and celecoxib, 10.0 mg/kg, once 
daily for 150 (±2) days yielded no difference in the clinical presentation, viral shedding, 
gross lesions, viral distribution, nor histopathology in cockatiels experimentally 
inoculated with PaBV-2 compared with birds not treated with a NSAID. Our results are 
in agreement with some reports,
13
 but conflicts with reports on the treatment of birds 
with clinical PDD.
14,16
 Differences in the species of birds treated, cockatiels 
experimentally inoculated with PaBV versus birds with PDD, may account for these 
disparate outcomes. Nevertheless, cockatiels experimentally inoculated with PaBV, 
whether or not treated with meloxicam and celecoxib, develop characteristics of PDD.   
In our study, black intestinal contents and pathological lesions consistent with 
PDD were observed in birds treated with meloxicam or celecoxib. In the studies of 
Hoppes et al., cockatiels inoculated with PaBV and treated with meloxicam exhibited 
gastrointestinal hemorrhage, while birds not infected with PaBV nor treated with 
meloxicam had no evidence of similar hemorrhage.
13
 In mammals, gastrointestinal 
abnormalities, such as ulcers and bleeding, and renal necrosis due to ischemia are major 
aspects of NSAID toxicity; however, most studies of NSAIDs in normal birds failed to 
report toxic effects.
78,81,86,88-91,94,95,96
  Cockatiels inoculated with PaBV and treated with 
NSAIDs may be at an increased risk for gastrointestinal abnormalities. A possible 
explanation of gastrointestinal bleeding and dark intestinal contents (presumably blood)  
36 
is that the administration of NSAIDs to a bird with gastrointestinal dysfunction, such as 
found in infections with PaBV, could exacerbate the potential for gastrointestinal 
irritation and toxicity. The birds in our study that had black intestinal contents had gross 
and histopathological lesions of the proventriculus and intestines consistent with PDD. 
The administration of NSAID to birds infected with PaBV did not alter weight 
loss or BCS. Birds that displayed severe signs of PDD or infection with PaBV, and were 
removed early or died, had decreased weight and BCS. Weight loss and poor BCS are 
commonly reported in the literature and is consistent with the gastrointestinal 
dysfunction that leads to starvation of birds.
3,10,13,20
 While most birds infected with PaBV 
decrease in weight, one bird in our study, number 2725, gained weight at the time of 
early removal from the study. Upon necropsy, the crop and proventriculus were 
distended with feed; this was most likely based on the gastrointestinal dysfunction 
caused by PaBV infection. Weight should not be used as the sole parameter to assess the 
progression of infection or disease, as the bird in question additionally had a decreased 
BCS, consistent with starvation but illness marked by enlarged crop, was lethargic and 
regurgitating prior to necropsy. (Table 2 and Figure 5B). 
Neither survival nor early removal from the study were different between the 
groups; however, the number of birds with clinical state warranting early removal was 
twice as high in the celecoxib group as compared with the control and meloxicam groups 
(Figure 2). However, this difference was not statistically significant, sample sizes were 
small, and this is the first study on celecoxib treatment of birds infected with PaBV. 
Even though the NSAIDs had no effect on mortality, the early removal of cockatiels 
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occurred between 33-79 days, consistent to the time period seen in other birds 
experimentally inoculated with PaBV.
3, 10, 11, 13, 20, 21
 Thirty to one hundred days is the 
common time period when birds experimentally inoculated with virus begin to develop 
clinical disease; however, Piepenbring et al. showed that clinical signs make take over 
150 days to occur in some cockatiels.
11
 These time frame differences in the appearance 
of clinical signs may be based on variations in viral inoculum, viral distribution, and the 
birds’ immune response. 
Gross findings showed no significance difference between birds in the three 
treatment groups. All groups had clinical presentations consistent with the progression of 
PDD described in literature.
3,10,11,13,20,21
 Clinical presentations most commonly seen were 
dilation of proventriculus, dilated crop, and undigested seed within the intestines (Figure 
5). These changes are a result of decrease in motility caused by the lymphocytic 
infiltration against the viral infection.
2,3,6,9,32,52 
 
Contrary to our hypothesis, NSAIDs treatments in cockatiels inoculated with 
PABV-2 did not significantly decrease lymphoplasmacytic distribution and severity. 
Histopathology showed similar lymphoplasmacytic infiltration among the three groups 
despite NSAID treatment,  related to PaBV inoculation manifesting to PDD.
3,10,11,13,21,52
 
Thus, the administration of meloxicam and celecoxib were not effective in reducing the 
inflammatory response seen in experimentally PaBV-2 inoculated cockatiels. 
No difference was seen in the shedding of PaBV as determined by mRNA 
detection on cloacal swab samples. Viral shedding was first detected on day 42 post-
inoculation and became more consistent on day 63 post-inoculation (Table 3). Five of 
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the eight birds that were euthanized or died early did not have mRNA detected in the 
cloaca at necropsy. Even though clinical signs are accompanied by histopathological 
changes in the brain of infected animals
101
 and these eight birds had histopathological 
lesions in the kidneys, virus may not be detected in the cloaca. The reasons for this are 
uncertain. Pathological changes may occur prior to virus levels in the tissue being at 
detectable levels. Though all eight birds had histopathological lesion in the kidney, four 
birds did not have viral mRNA detected in the kidney. Thus virus may not have been 
shed into the urine and secondarily being in the cloaca; these four birds were also 
negative for mRNA on cloaca swabs. An additional possibility is that the amount of 
virus in the cloaca, and collected on the cloacal swab, may have been lower than the 
limit of detection for the RT-PCR. For one of the five birds negative on the cloacal 
swab, viral mRNA was detected in the kidney. It would have been useful to have done 
an IHC assay for PaBV on the kidneys of these eight birds. Unfortunately, IHC was done 
only on the brain and proventriculus of the birds that were removed early from the study. 
By day 84 post-inoculation all but two surviving birds were shedding virus and at 
the end of the study, all the surviving birds, except for one, were shedding virus. In our 
study, detection of PaBV on cloacal swabs was inconsistent in 3 of 19 birds (Table 3), 
which was similar to the intermittent shedding of the virus as noted by other 
investigators 
20,23,52,56
 As stated earlier, the question arises whether or not this is 
intermittent shedding or a factor of low levels of the virus present at collection. Birds 
may be PCR-negative on fecal swabs and PCR-positive for PaBV in urine.
56
 Collecting 
multiple samples per bird during the day and pooling them for testing alleviate the 
39 
negative cloacal results but pooling of five uro-fecal samples per day for 5 consecutive 
days but may still result in inconsistent PCR findings.
52
 
One bird, number 261, was negative for the presence of PaBV by all tests 
throughout the study; however at necropsy, the proventriculus was dilated and contained 
undigested seed. Histopathology showed perivascular cuffing with increased glial cells 
in the brain and lymph nodules in the mucosa, ganglia, and serosa of the ventriculus of 
this bird. Cryptosporidium identified in the proventriculus may have contributed to the 
dilation and histopathological lesions in the ventriculus.
102
 
The administration of NSAIDs did not affect distribution or viral load of the 
tissues. No differences between treated and untreated birds were expected as NSAIDs 
are anti-inflammatory in action but not antiviral.  Virus was detected most often in 
nervous, gastrointestinal, heart and kidney tissues but was also found in many other 
organs: lungs, mucosa of the trachea, eye, liver, gallbladder, skin, feather follicles, 
oviduct, pancreas, and gonads. Parrot bornavirus is neurotropic but also has a broad 
tissue tropism, which does not always correlate with degeneration, necrosis, and/or 
inflammation of these tissues
11,20,33,51,52,54,56
 
Conclusion 
The administration of meloxicam or celecoxib did not alter the progression or 
severity of clinical signs, pathological changes, viral shedding, or viral RNA distribution 
in cockatiels experimentally infected with PaBV-2. There is therefore no justification for 
continuing the practice of administering NSAIDs to birds with clinical PDD.  Since 
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NSAID treatment of birds may have a synergistic effect on gastrointestinal dysfunction 
resulting in toxicity and undesirable side effects such as gastrointestinal irritation and 
bleeding, this is an entirely inappropriate treatment modality for PDD cases.  It may be 
argued that NSAIDs, while totally ineffective in treating cockatiels, may be of benefit in 
treating other parrot species. This is highly unlikely. Unless proven otherwise NSAID 
use in PDD cases should be discontinued immediately.   
 
 
 
 
 
 
 
41 
REFERENCES 
1. Honkavuori KS, Shivaprasad HL, Williams BL, et al. Novel bornavirus in
psittacine birds with proventricular dilatation disease. Emerg Infet Dis 2008; 
14:1883-1886. 
2. Kistler AL, Gancz A, Clubb S, et al. Recovery of divergent avian bornaviruses
from cases of proventricular dialatation disease: identification of a candidate 
etiologic agent. Virol J 2008; 5:88-102 
3. Gray P, Hoppes S, Suchodolski P, et al. Use of avian bornavirus isolated to
induce proventicular dilatation disease in conures. Emerg Infec Dis 2010; 
16:473-479. 
4. Doneley RJT, Miller RI, Fanning TE. Proventricular dilatation disease: an
emerging exotic disease of parrots in Australia. Aust Vet J 2007; 85:119-123. 
5. Gancz AY, Clubb S, Shivaprasad HL, et al. Advanced diagnostic approaches and
current management of proventricular dilatation disease. Vet Clin North Am 
Exot Anim Pract 2010; 13:471-494. 
6. Hoppes S, Gray PL, Payne S, et al. The isolation, pathogenesis, diagnosis,
transmission, and control of avian bornavirus and proventricular dilatation 
disease. Vet Clin North Am Exot Anim Pract 2010; 13:495-508. 
7. Shivaprasad HL, Barr BC, Woos LW et al. Spectrum of lesions (Pathology) of
proventricular dilatation syndrome, in Proceedings. Annu Conf Assoc Avian Vet 
1995; 505-506. 
 42 
 
8. Berthane Y, Smith DA, Newman S, et al. Peripheral neuritis in psittacine birds 
with perventricular dilatation disease. Avian Pathol 2001; 30:563-570. 
9. Ouyang N, Storts R, Tian Y, et al.  Histopathology and the detection of avian 
bornavirus in the nervous system of birds diagnosed with proventricular 
dilatation disease. Avian Pathol 2009; 38:393-401. 
10.  Mirhosseini N, Gray PL, Hoppes S, et al. Proventricular dilatation disease in 
cockatiels (Nymphicus hollandicus) after infection with a genotype 2 avian 
bornavirus. J Avian Med Surg 2011; 25:199-204. 
11.  Piepenbring AK, Enderlein D, Herzog S, et al. Pathogenesis of avian bornavirus 
in experimentally infected cockatiels. Emerg Infect Dis 2012; 18:234-241. 
12. Hoppes S, Tizard I, Shivaprasad HL. Avian Bornavirus and proventricular 
dilatation disease. diagnostics, pathology, prevalence, and control. Vet Clin Exot 
Anim 2013; 16:339-355. 
13. Hoppes S, Heatley J J, Guo JH, et al. Meloxicam treatment in cockatiels 
(Nymphicus hollandicus) infected with avian bornavirus. J Exot Pet Medicine 
2013; 22:275-279. 
14. Dalhausen B, Aldred, S Colaizzi E, et al. Resolution of the clinical proventricular 
dilatation disease by cycloxgenase 2 inhibition, in Proceedings. Annu Confere: 
Assoc Avian Vet 2002; 9-12. 
15. Bird Channel website. Proventricular dilatation disease review 2005. Avalible at: 
www.birdchannel.com/bird-diet-and-health/bird-diseases/bird-diseases-pdd.aspx 
Accessed May 20, 2015 
43 
16. Clubb SL. Clinical management of psittacine birds affected with proventricular
dilatiation disease, in Proceeding Annu Confere: Assoc Avian Vet 2006; 85-90. 
17. Beauty of Birds website. Research and advances in avian bornavirus (ABV) and
proventricular dilatation disease (PDD): Signs of ABV infection and systems 
affected. Available at: www.beautyofbirds.com/pddtreatment.html. Accessed 
May 20, 2015 
18. Veterinary Partner.com website. Proventricular dilatation disease (PDD).
Available 
at:www.veterinarypartner.com/Content.plx?P=A&C=189&A=3134&S=0. 
Accessed May 20, 2015 
19. St. Francis Animal & Bird Hospital Library website. Available at
:www.stfrancisanimalandbird.com/ResourcesLibrary/?page_id=12. Accessed 
May 20, 2015 
20. Payne S, Shivaprasad HL, Mirhosseini N, et al. Unusual and severe lesions of
proventricular dilatation disease in cockatiels (Nymphicus hollandicus) acting as 
healthy carriers of avian bornavirus (ABV) and subsequently infected with a 
virulent strain of ABV. Avian Pathol 2011; 40:15-22. 
21. Gancz, AY, Kistler AL, Greninger AL, et al. Experimental induction of
proventricular dilatation disease in cockatiels (Nymphicus hollandicus) 
inoculated with brain homogenates containing avian bornavirus 4. Virol J 2009; 
100. 
 44 
 
22. Villanueva I, Gray P, Mirhosseini N, et al. The diagnosis of proventricular 
dilatation disease: Use of a Western blot assay to detect antibodies against avian 
Borna virus. Vet Microbiol 2010; 143:196-201. 
23. Rubbenstroth D, Brosinski K, Rinder M, et al. No contact transmission of avian 
bornavirus in experimentally infected cockatiels (Nymphicus hollandicus) and 
domestic canaries (Serinus canaria forma domestica). Vet Microbiol 2014; 
172:146-156. 
24. Wust E, Mahlberg S, Enderlein D, et al. Experimanally infection of cockatiel 
(Nymphicus hollandicus) eggs with avian bornavirus, in Proceedings. ICARE 
2015; 258. 
25. Kuhn J, Dürrwald R, Bào Y, et al. Taxonomic reorganization of the family 
Bornaviridae. Arch of Virol 2015; 160:621-632. 
26. Pyper JM, Clements JE, Zink MC.The nucleolus is the site of Borna disease virus 
RNA transcription and replication.  J Virol 1998; 72:7697-7602. 
27. Cubitt B, Oldstone C, Valcarcel J, et al. RNA splicing contributes to the 
genteration of mature mRNAs of Borna disease virus, a non-segmented negative 
strand RNA virus. Virus Res 1994; 34:69-79. 
28. Schneemann A, Schneider PA, Kim S, et al. Identification of signal sequances 
that control transcription of borna disease virus, a nonsegmented, negative strand 
RNA, virus. J Virol 1994; 68:6514-6522. 
29. Schneider Pa, Schneemann A, Lipkin WI. RNA splicing in Borna disease virus, a 
nonsegmented, negative-stranded RNA virus. J Virol 1994; 68:5007-5012. 
 45 
 
30. Reuter A, Ackermann A, Kothlow S, et al. Avian Bornaviruses Escape 
Recognition by the Innate Immune System. Viruses 2010; 2:927-938. 
31. Schneider PA, Briese T, Zimmermann W, et al. Sequance conservation in field 
and experimantal isolates of Borna disease virus. J Virol 1994; 68:63-68. 
32. Payne SL, Delnatte P, Guo JH, et al. Birds and bornavirus. Anim Heal Res Rev 
2012; 13:145-156. 
33. de Kloet SR, Dorrestein GM. Presence of avian bornavirus RNA and anti-avian 
bornavirus antibodies in apparently healthy macaws. Avian Dis 2009; 53:568-
573.  
34. Mirhosseini N, Gray PL, Tizard I, et al.  Complete genome sequence of avian 
bornavirus genotype 1 from a macaw with proventricular dilatation disease. J 
Virol 2012; 86:7023. 
35. Weissenböck H, Bakonyi T, Sekulin K, et al. Avian Bornaviruses in Psittacine 
Birds from Europe and Australia with Proventricular Dilatation Disease. Emerg 
Infec Dis 2009; 15:1453-1459. 
36. Kistler Al, Smith JM, Greninger AL, et al. Analysis of naturally occurring avian 
bornavirus infection and transmission during an outbreak of proventricular 
dilatation disease among captive psittacine birds. J Virol 2010; 84:2176-2179. 
37. Staeheli P, Rinder M,  Kaspers B. Avian bornavirus associated with fatal disease 
in psittacine birds. J Virol 2010; 84:6269-6275. 
 46 
 
38. Nedorost N, Maderner A, Kolodziejek J. Identification of mixed infections with 
different genotypes of avian bornaviruses in psittacine birds with proventricular 
dilatation disease.  Avian Dis 2012; 56:414-417. 
39. Last RD, Weissenbock H, Nedorost N, et al. Avian bornavirus genotype 4 
recovered from naturally infected psittacine birds with proventricular dilatation 
disease in South Africa. J South African Vet Assoc 2012; 83:4. 
40. Rubbenstroth D, Rinder M, Kaspers B,et al. Efficient isolation of avian 
bornaviruses (ABV) from naturally infected psittacine birds and identification of 
new ABV genotype from a salmon-crested cockatoo (Cacatua molaccensis). Vet 
Microbiol 2012; 161:36-42. 
41. Encinas-Nagel N, Enderlein D, Piepenbring A et al. Avian bornavirus in free-
ranging psittacine birds, brazil. Emerg Infec Dis 2014; 20:2103-2106. 
42. Weissenböck H, Sekulin K, Bakonyi T, et al. Novel avian bornavirus in a 
nonpsittacine species (Canary; Serinus canaria) with enteric ganglioneuritis and 
encephalitis. J Virol 2009; 83:11367-11371. 
43. Rinder M, Dorobek K, Liepert A, et al. Avian bornaganglioneuritis in canaries 
(Serinus Canaria F. Domestica) Naturally infected with avian bornaviruses, in 
Proceedings. ICARE 2015; 256. 
44. Rubbenstroth D, Rinder M, Stein M, et al. Avian bornavirus are widely 
distributes in canary birds (Serinus canaria f. domestica). Vet Microbiol 2013; 
165:287-295. 
 47 
 
45. Rubbenstroth D, Schmidt V, Rinder M, et al. Discovery of new avian bornavirus 
genotype in estridid finches (Estrildidae) in Germany. Vet Microbiol 2014; 
168:318-323. 
46. Delnatte P, Berkvens C, Kummrow M, et al. New genotype of avian bornavirus 
in wild geese and trumpeter swans in Canada. Vet Record 2011; 169:108-108. 
47. Payne SL, Covaleda L, Guo JH, et al. Detection and characterization of a distinct 
bornavirus lineage from healthy Canada geese (Branta canadensis) J Virol 2011; 
85:120530-120536. 
48. Guo JH, Baroch J, Randall A, et al. Complete genome sequence of an avian 
bornavirus isolated from a healthy Canadian goose (Branta canadensis). Am 
Soci Microbiol 2013; 1:e00839-13. 
49. Guo JH, Shivaprasad HL, Rech RR, et al. Characterization of a new genotype of 
avian bornavirus from wild ducks. Virol J 2014; 11:197. 
50. Villanueva I, Gray P, Tizard I. Detection of an antigen specific for proventicular 
dilatation disease in psitticine birds. Vet. Rec 2008; 163:426. 
51. Rinder M, Ackermann A, Kempf H, et al. Broad tissue and cell tropism of avian 
bornavirus in parrots with proventricular dilatation disease. J. Virol 2009; 755-
756. 
52. Raghav R, Taylor M, DeLay J, et al. Avian bornavirus is present in any tissues of 
psittacine birds with histopathologic evidance of proventicular dilatation disease. 
J Vet Diagn Invest 2010; 22:495-508. 
 48 
 
53. Wunschmann A, Honkavouri K, Briese T, et al., Antigen tissue distribution of 
avian bornavirus (ABV) in psittacine birds with natural proventicular dilatation 
disease and ABV genotype 1 infection. J Vet Diagn Invest 2011; 23:716-726. 
54. Delnatte P, Mak M, Ojkic D, et al. Detection of avian bornavirus in multiple 
tissues of infected psittacine birds using real-time reverse transcription 
polymerase chain reaction, J Vet Diagn Invest 2014; 26:266-271. 
55. Weissenböck H, Fragner K, Nedorost N, et al. Localization of avian bornavirus 
RNA by in situ hybridization in tissues of psittacine birds with proventricular 
dilatation disease. Vet Microbiol, 2010; 145:9-16. 
56. Heatley JJ, Villalobos AR. Avian bornavirus in the urine of infected birds. Vet. 
Med Res Rep 2012; 3:19-23. 
57. Escandon P, Loewinger MN, Heatley JJ, et al. Infectivity of avian bornavirus 
positive urine from African grey parrots with proventricular dilatation disease, in 
Proceedings. ICARE 2015; 465. 
58. de Kloet AH, Kerski A, de Kloet SR. Diagnosis of avian bornavirus infection in 
psittaciformes by serum antibody detection and reverse transcription polymerase 
chain reaction assay using feather calami. J Vet Diagn Invest 2011; 23:421-429. 
59. Lierz M, Piepenbring A, Herden C, et al. Vertical transmission of avian 
bornavirus in psittacines. Emerg Infect Dis 2011; 17:2390-2391. 
60. Kerski A, de Kloet AH, de Kloet  SR. Vertical transmission of avian bornavirus 
in psittaciformer: avian bornavirus RNA and anti-avian bornavirus antibodies in 
 49 
 
eggs, embryos, and hatchings oobtained from infected sun conures (Aratinga 
solstitialis). Avian Dis 2012; 56:471-478. 
61. Monaco E, Hoppes S, Guo JH, et al. The detection of avian bornavirus within 
psittacine eggs. J Avian Med Surg 2012; 26:144-148. 
62. Heckmann J, Enderlein D, Piepenbring A, et al. Investigation on different routes 
of transmission of Avian bornavirus in cockatiels (Nymphicus hollandicus), in 
Proceedings. ICARE 2015; 326. 
63. Delnatte P,  Nagy E, Ojkic D, et al.  Investigation into the possibility of vertical 
transmission of avian bornavirus in firee-ranging Canada geese (Branta 
canadensis) Avian Pathol 2014; 43:301-304. 
64. Clark D. Proventicular dilatation syndrome in large birds. Avian Dis 1984; 
28:813-815. 
65. Gregory RC, Latimer KS, Niagro FD, et al. A Review of Proventricular 
Dilatation Syndrome. J Assoc Avian Vet 1994; 8:69-75. 
66. Steinmetz A, Pees M, Schmidt V, et al. Blindness as a sign of proventricular 
dilatation disease in a grey parrot (Psittacus erithacus erithacus). J  Small 
Animal Pract 2008; 49:660-662. 
67. Escandon P, Heatley JJ, Kranz JB, et al. Effects of ribavirin on avian bornavirus 
in duck embryonic fibroblast cell culture, in Proceeding ICARE 2015; 329. 
68. Musser JMB, Heatley JJ, Koinis AV, et al.  Ribavirin inhibits parrot bornavirus 4 
replication in cell culture. PLoS ONE 2015. In Press. 
 50 
 
69. Flower R. Effects of anti-inflammatory drugs on prostaglandin biosynthesis. 
Nature. New Biology 1972; 238:104-106. 
70. Vane JR, Botting RM, Mechanism of action of asprin-like drugs. Semm Arthritis 
Rheum 1997; 26:2-10. 
71. Smith TJ. Cyclooxigenase as a principal targets for the action of NSAIDs. 
Rheum Dis Clin North Am 1998; 24:501-523. 
72. Furst DE. Meloxicam: selective COX-2 inhibition in clinical practice. Sem Arth 
Rhem 1997; 26:21-27. 
73. Flower RJ. The development of COX2 inhibitors. Nature Revi Drug Disc 2003; 
2:179-191. 
74. Bergh MS, Budsberg SC. The coxib NSAIDs: potential clinical and 
pharmacologic importance in veterinary medicine. J Vet Intern Med 2005; 19: 
633-643. 
75. Klein PN, Charmatz K, Langenberg J. The effects of flunixin meglumine 
(Banamine) on the renal function in northern bobwhite (colinus virginianus): an 
avian model, in Proceeding s. Annu Conf Am Assoc Zoo Vet 1994; 112-114. 
76. Oaks JL, Gilbert M, Virani MZ. et al. Diclofenac residues as the cause of vulture 
population decline in Pakistan. Nature 2004; 427:630-633. 
77. Swan G, Naidoo V, Cuthbert R, et al. Removing the threat of diclofenac to 
critically endangered Asian vultures.PLoS biology 2006; 4:e66. 
 51 
 
78. Swarup D, Patra RC, Prakash V, et al. Safety of meloxicam to critically 
endangered Gyps vultures and other scavenging birds in India. Animal Conserv 
2007; 10:192-198. 
79. Naidoo V, Wolter K, Cromarty D, et al.The pharmacokinetics of meloxicam in 
vultures. J Vet Pharmacol Ther 2008; 31:128-134. 
80. Naidoo V, Wolter K, Cromarty D, et al. toxicity of non-steroidal anti-
inflammatory drugs to Gyps vultures: a new threat from ketoprofen . Biol Lett 
2010; 6:339-341. 
81. Pereira ME, Werther K, Evaluation of the renal effects of flunixin meglumine, 
ketoprofen and meloxicam in budgerigars (Melopsittacus undulatus). Vet Res 
2007; 160:844-846. 
82. Musser JMB, Heatley JJ, Phalen DN. Pharmacokinetics after intravenous 
administration of flunixin meglumine in budgerigars (Melopsittacus undulatus) 
and Patagonian conures (Cyanoliseus patagonus). J Am Vet Med Assoc 2013; 
242:205-208. 
83. Baert K, De Backer P. Comparative pharmacokinetics of three non-steroidal anti-
inflammatory drugs in five bird species. Comp Biochem Physiol C Toxicol 
Pharmacol 2003; 134:25-33.  
84. Hussain I, Khan Z, Khan A, et al. Toxicological effects of diclofenac in four 
avian species. Avian Pathol 2008; 37:315-321.  
 52 
 
85. Zollinger TJ, Hoover JP, Payton ME, et al. Clinicopathologic, gross necropsy 
and histolofic findings after intramuscular injection of carprofen in a pigeon 
(Columba livia) model. J Avian Med Surg 2011; 25:173-184. 
86. Desmarchelier M, Troncy E, Fitzgerald G, et al., Analgesic effects of meloxicam 
administration on postoperative orthopedic pain in domestic pigeons. (Columba 
livia). Am J Vet Res 2012; 73:361-367. 
87. Sinclair KM, Church ME, Farver TB, et al. Effects of meloxicam on hematologic 
and plasma biochemical analysis variables and results of histologic examination 
of tissues specimens of Japanese quail (Coturnix japonica). Am J Vet Res 2012; 
73:1720-1727. 
88. Montesinos A, Ardiaca M, Bonvehi C, et al. Plasma and urinary levels of n-
acetyl-ss-d-glucosaminidase in healthy african grey parrots (Psittacus erithacus) 
and after a treatment with meloxicam, in Proceedings. ICARE 2015; 336. 
89. Montesinos A, Ardiaca M, Juan-Sallés C, et al. Effects of meloxicam on 
hematologic and plasma biochemical analyte values and results of histologic 
examination of kidney biopsy specimens of african arey parrots ( Psittacus 
erithacus). J Avian Med Surg 2015; 29:1-8. 
90. Antonissen G, Martel A, Goessens T, et al. Comparative pharmacokinetics of 
celecoxib and mavacoxib in cockatiels (Nymphicus hollandicus, in Proceedings. 
ICARE 2015; 400. 
91. Summa N, Fitzgerald G, Larrat S, et al. Evaluation of toxicity of meloxicam in 
american kestrels (Falco sparverius), in Proccedings. ICARE  2015; 335. 
 53 
 
92. Baert K, De Backer P. Disposition of sodium salicylate, flunixmin and 
meloxicam after intravenous administration in broiler chickens. J Vet Pharmacol 
Ther 2002; 25:449-453. 
93. Cetinkal, A.. The effects of meloxicam on neural tube development in the early 
stage of chick embryos. Turkish neurosurgery, 2010; 20:111-116. 
94. Molter CM, Court MH, Cole GA, et al. Pharmacokinetics of meloxicam after 
intravenous, intramuscular, and oral administration of a signle dose to 
Hispaniolan Amazon parrots (Amazona ventralis). Am J Vet Res 2013; 74:375-
380. 
95. Dijkstra B, Guzman DSM, Gustavsen K, et al. Renal, gastrointestinal, and 
hemostatic effects of oral administration of meloxicam to Hispaniolan Amazon 
parrots (Amazona ventralis). Am J Vet Res 2015; 76:308-317. 
96. Lacasse C, Gamble KC, Boothe DM. Pharmacokinetics of a single dose of 
intravenous and oral meloxicam in red-tailed hawks (Buteo jamaicensis) and 
Great horned owls (Bubo virginianus). J Avian Med Surg 2013; 27:204-210. 
97. Hocking P M, Robertson GW, Gentle MJ. Effects of non-steroidal anti-
inflammatory drugs on pain-related behaviour in a model of articular pain in the 
domestic fowl. ReseVet Sci 2005; 78:69-75. 
98. Patrono C, Patrignani P, Rodriguez GLA. Cyclooxygenase-selective inhibition of 
prostanoid formation: transducing biochemical selectivity into clinical read-outs. 
J Clin Invest 2001; 108:7-13 
 54 
 
99. Guo JH, Payne S, Zhang S, et al. Avian bornaviruses: diagnosis, isolation, and 
genotyping. Curr Protoc Microbiol 2014; 34:15i.11.11-15i.11.33. 
100. Heatley JJ. Introduction to avian practice: The Basic, in Proceedings. Michigan 
Vet Conf 2015. 
101. Morimoto K, Hooper DC, Bornhorst A, et al. Intrinsic responses to 
Borna disease virus infection of the central nervous system., in Proceedings. Nat 
Acad Sci 1996; 9313345-13350. 
102. Ravich ML, Reavill DR, Hess L, et al. Gastrointestinal cryptosporidiosis in 
captive psittacine birds in the United States: a case review. J Avian Med Surg 
2014; 28:297-303. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 55 
 
Bird ID -31 6 19 26 33 37 41 43 45 48 54 55 61 63 69 74 76 79 84 90 97 104 111 118 125 132 139 146 153 160 168 173±2
*237 102 104 108 101 100 101 98.5 95
*302 100 89.5 95 89 89 87 86.5 91.5 74.8
236 115 113 118 116 107 104 107.5 100.5 102 105.5 109 110 110 112.5 112 111 110 108.5 108.5 107.5 105.5 105 103 107 102
239 81 78 79 76.5 75 68.5 69.5 70.5 71 72 75 77.5 78 77.5 77 77 81 85 85 84.5 86 83 82.5 83 80.5
791 127 117 123 120 95 94.5 102.5 106 107 108.5 108.5 109 115 119 122 122 122 122.5 122.5 124.5 124 112.4 122 128 121.2
9491 91 94.5 98 94 94 93.5 96 94 93 92.5 95 99 99.5 99 98.5 99 100 98 97.5 97 96 98.5 95.5 97.5 99.2
92 96 88 90.5 87 85 85 83.5 82 86.5 84 84 85 84 85 85 85 86.5 84.5 85 86.5 83.5 84.5 82 83 86
2820 83 91 90 85 89 88 86 84.5 84 85 86.5 86.5 85.5 86.5 84 84 89 89 89.5 88.5 87 87 87 85 87
1460 96 94.5 100 98.5 95 94.5 90 82 92 96.5 100.5 102.5 103 104.5 102 102 104 105 105.5 101 106 105.5 103.5 103.5 93.9
*10 88 91.5 94 86 76
*2725 114 112 119 104 93 96 92.5 94.5 107.5 112 121 117.6
1662 82 83 88.5 77 74 72 78 78.5 79.5 79.5 82 84 85 87.5 87.5 88.5 88.5 89.5 88.5 88.5 89 89.5 87 90 93.6
254 98 93.5 95 88.5 84 87.5 86.5 87 93.5 97.5 97.5 98.5 101 99 104 104 102.5 102 94 86 84 87.5 93 100 98.5
691 100 108 112 106 98 100 95 101.5 105 104 102.5 103.5 102 103 101 103 105 103.5 103.5 106 105.5 105.5 109.5 112.5 106.5
210 109 93 105 94.5 94 97 95 90.5 90.5 89 91 95 95.5 97.5 96 98.5 100 93 90 96 91 93 92 92 85
229 112 107 107 103 102 92 94.5 93.5 94 91 96 97.5 96 98 94.5 97.5 98.5 98.5 98.5 101 100.5 102 103 104 101
221 98 91 98 90 84 92 90 89.5 91 93 92.5 94 94 94.5 91.5 91.5 92 93 92 93.5 94 94 95 97.5 94.6
261 125 107 112 100 80 85 87.5 90 87 88.5 90 91 90 91 91.5 95.5 97 99 99.5 100.5 102 105.5 110 112 107.5
*204 122 111 121 116 92 97
*241 86 85 84 83.5 69 72 74.5
*2441 105 97 101 97 79 89.5 83
*196 79 76.5 78.5 75.5 75 72 69.5 69 71 70 63.6
265 145 124 134 132 124 105 109 110 108 106 103.5 105 106 107.5 108.5 109 110 112.5 109.5 109.5 111 112.5 112 112.5 115
297 91 92 92 90 87 86.5 88.5 83.5 85 86 90 92 92 93.5 90 90 89 88 88.5 89 88.5 89 88.5 90 85.9
215 100 93.5 92 88.5 89 95 93 93 96 98 96 98 97.5 99 100 103 102 103.5 106.5 106.5 108.5 103.5 98.5 97 93.8
247 104 96 99 95 91 93 95 91.5 93.5 95 94 96.5 97.5 96.5 94 95 95 95 96 94 93.5 93 94.5 94.5 93.5
279 91 92 95 92 85 90 90 91 96 95 93 96 96 95.5 94 96.5 95 96.5 98 97 98 98 96 96.5 95
Weights
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   (g) grams   (*) euthanized prior to the end of study
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Bird ID -31 6 33 33 37 41 43 45 48 54 55 61 63 69 74 76 79 84 90 97 111 118 125 132 139 146 153 160 168 173±2
*237 3 3 4 3 4 3
*302 3 3 3 3 3 3 2
236 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 4
239 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 3 3 2 2 2 2 3
791 4 3 3 3 4 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 4
9491 2 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 2
92 3 3 3 3 3 3 3 3 3 3 3 3 2 3 2 3 3 3 3 3 3 4
2820 1 2 2 2 2 2 2 2 2 2 3 2 2 2 3 2 2 2 2 2 3
1460 2 3 3 4 3 2 2 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
*10 2 3 1 1
*2725 3 3 2 3 3 3 3 2 2 2
1662 3 2 3 2 3 2 3 3 3 3 3 3 3 3 3 3 3 3 3 4
254 3 3 3 3 3 2 3 3 3 3 3 3 3 3 3 3 2 2 2 2 2 3
691 2 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 4
210 4 2 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 2
229 3 3 3 2 3 2 3 2 3 3 3 3 3 3 3 3 3 3 3 3 3 4
221 2 2 2 2 3 2 3 3 3 2 3 3 2 3 3 2 2 2 3 2 2 3
261 4 3 2 2 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
*204 4 3 2 2
*241 3 2 2 2 2
*2441 3 3 3 3 3
*196 2 2 2 2 2 2 2 2 1
265 3 5 4 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 4
297 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
215 3 2 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 4
247 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
279 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 4
Ce
le
co
xi
b
     (*) euthanized prior to the end of study
Co
nt
ro
l
M
el
ox
ic
am
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Days of inoculation 
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APPENDIX B 
 
Schubot Necropsy Report 
*TAMU 237- Nymphicus hollandicus  
Necropsy done on 14 May 2014 by Paulina Escandon at 11:15AM 
History: Bird was previously inoculated with Parrot bornavirus-2 and was part of the 
Meloxicam/Celecoxib study; housed in isolation building 1044 in BSL2 room 6, Group 
1. Bird found off balance; possible neurologic symptoms. Bird was euthanized by Dr. 
Heatley at 11:00AM. Blood was collected. 
 Necropsy Report: Weight- ~95 
 Air sacs enlarged 
 Body condition score- 3 of 5 
 Crop- normal 
 PV- normal 
 V - normal 
 Intestines- normal 
 Cloaca- normal 
 Adrenals- normal 
 Liver- normal 
 Spleen- normal 
 Kidney- normal 
 Heart- normal 
 Lung- normal 
 Sciatic nerve- normal 
 Brach. plex.- normal 
 Pancreas- normal 
 Gonads- testes (male- 1 undeveloped testis) 
 Brain- visible blood surrounding brain 
 Spinal cord- normal 
 Eye- normal 
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Schubot Necropsy Report 
*RAATX 302- Nymphicus hollandicus  
Necropsy done on 21 May 2014 by Paulina Escandon at 11:15AM 
History: Bird was previously inoculated with Parrot bornavirus-2 and was part of the 
Meloxicam/Celecoxib study; housed in isolation building 1044 in BSL2 room 6, Group 
1. Bird found experiencing regurgitation with a distended crop. Bird was euthanized by 
Paulina. Bird regurgitated during euthanasia. Blood was collected. 
 
Necropsy Report: 
 Air sacs clear 
 Body condition score- 2 of 5 
 Crop- Enlarged 
 PV-slightly distended. 
 V - abnormal 
 Intestines- discoloration 
 Cloaca- normal 
 Adrenals- normal 
 Liver- normal 
 Spleen- normal 
 Kidney- normal 
 Heart- normal 
 Lung- discoloration 
 Sciatic nerve- normal 
 Brach. plex.- normal 
 Pancreas- discoloration 
 Gonads- testes (male- 1 undeveloped testis) 
 Brain- normal 
 Spinal cord- normal 
 Eye- normal 
 Weight- 74.8g 
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Schubot Necropsy Report 
TAMU 236- Nymphicus hollandicus  
Necropsy done on 12 September 2014 by Dr. Gentry at 1:30PM 
History: Bird was previously inoculated with Parrot bornavirus-2 and was part of the 
Meloxicam/Celecoxib study; housed in isolation building 1044 in BSL2 room 6, Group 
1 . End of study necropsy performed. Blood and urine was collected prior to euthanasia.   
 
Necropsy Report: 
 Air sacs- normal   
 Excellent fat stores 
 Body condition score- 3 of 5 
 Crop-normal  
 PV- normal 
 V- normal 
 Intestines-normal 
 Cloaca- normal 
 Adrenals- normal 
 Liver-normal  
 Spleen- enlarged 
 Kidney-normal 
 Heart-1.2g  enlarged 
 Lung- normal  
 Sciatic nerve- normal 
 Brach. plex.- normal 
 Pancreas- normal 
 Gonads- ovaries  (female) 
 Brain- normal 
 Spinal cord- normal 
 Eye- normal 
 Weight-102g 
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Schubot Necropsy Report 
TAMU239- Nymphicus hollandicus  
Necropsy done on 12 September 2014 by Dr. Gentry at 1:30PM 
History: Bird was previously inoculated with Parrot bornavirus-2 and was part of the 
Meloxicam/Celecoxib study; housed in isolation building 1044 in BSL2 room 6, Group 
1. End of study necropsy performed. Blood and urine was collected prior to euthanasia.   
 
Necropsy Report: 
 Air sacs- normal   
 Excellent fat stores 
 Body condition score- 3 of 5 
 Crop-normal  
 PV- normal 
 V- normal 
 Intestines-normal 
 Cloaca- normal 
 Adrenals- normal 
 Liver-normal 
 Spleen- normal 
 Kidney-normal 
 Heart-0.6g  
 Lung- normal 
 Sciatic nerve- normal 
 Brach. plex.- normal 
 Pancreas- normal 
 Gonads- testis  (male) 
 Brain- normal 
 Spinal cord- normal 
 Eye- normal 
 Weight-80.5 g 
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Schubot Necropsy Report 
RAATX 791- Nymphicus hollandicus  
Necropsy done on 12 September 2014 by Dr. Gentry at 1:30PM 
History: Bird was previously inoculated with Parrot bornavirus-2 and was part of the 
Meloxicam/Celecoxib study; housed in isolation building 1044 in BSL2 room 6, Group 
1. End of study necropsy performed. Blood and urine was collected prior to euthanasia.  
 
Necropsy Report: 
 Air sacs- normal   
 Body condition score- 4 of 5 
 Crop-normal  
 PV- slightly dilated 
 V- normal 
 Intestines-normal 
 Cloaca- normal 
 Adrenals- normal 
 Liver-normal 
 Spleen- slightly enlarged 
 Kidney-normal 
 Heart-1.2g enlarged 
 Lung- normal 
 Sciatic nerve- normal 
 Brach. plex.- normal 
 Pancreas- normal 
 Gonads- ovaries (female) 
 Brain- normal 
 Spinal cord- normal 
 Eye- normal 
 Weight-121.2 g 
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Schubot Necropsy Report 
MRTFL 9491- Nymphicus hollandicus  
Necropsy done on 12 September 2014 by Dr. Gentry at 1:30PM 
History: Bird was previously inoculated with Parrot bornavirus-2 and was part of the 
Meloxicam/Celecoxib study; housed in isolation building 1044 in BSL2 room 6, Group 
1. End of study necropsy performed. Blood and urine was collected prior to euthanasia.  
 
Necropsy Report: 
 Air sacs- normal   
 Body condition score- 3 of 5 
 Crop-normal full of seed  
 PV- slightly dilated 
 V- normal 
 Intestines-normal 
 Cloaca- normal 
 Adrenals- normal 
 Liver-normal 
 Spleen- slightly enlarged 
 Kidney-normal 
 Heart-1.1g enlarged 
 Lung- normal 
 Sciatic nerve- normal 
 Brach. plex.- normal 
 Pancreas- normal 
 Gonads- ovaries (female) 
 Brain- normal 
 Spinal cord- normal 
 Eye- normal 
 Weight-99.2 g 
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Schubot Necropsy Report 
RAATX 92- Nymphicus hollandicus  
Necropsy done on 12 September 2014 by Dr. Gentry at 1:30PM 
History: Bird was previously inoculated with Parrot bornavirus-2 and was part of the 
Meloxicam/Celecoxib study; housed in isolation building 1044 in BSL2 room 6, Group 
1. End of study necropsy performed. Blood and urine was collected prior to euthanasia.   
 
Necropsy Report: 
 Air sacs- normal   
 Excellent fat stores 
 Keel score- 3 
 Crop-normal  
 PV- normal 
 V- normal 
 Intestines-normal 
 Cloaca- normal 
 Adrenals- normal 
 Liver-mottling, blood vessels presently visible  
 Spleen- enlarged 
 Kidney-normal 
 Heart-0.8g  
 Lung- normal 
 Sciatic nerve- normal 
 Brach. plex.- normal 
 Pancreas- normal 
 Gonads- testis (male) 
 Brain- normal 
 Spinal cord- normal 
 Eye- normal 
 Weight-86g 
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Schubot Necropsy Report 
MRTFL 2820- Nymphicus hollandicus  
Necropsy done on 12 September 2014 by Dr. Gentry at 1:30PM 
History: Bird was previously inoculated with Parrot bornavirus-2 and was part of the 
Meloxicam/Celecoxib study; housed in isolation building 1044 in BSL2 room 6, Group 
1. End of study necropsy performed. Blood and urine was collected prior to euthanasia.  
Necropsy Report: 
 Air sacs- normal   
 Keel score- 2 
 Crop-normal  
 PV- normal 
 V- normal 
 Intestines-normal 
 Cloaca- normal 
 Adrenals- normal 
 Liver-normal 
 Spleen- normal 
 Kidney-normal 
 Heart-0.9g enlarged 
 Lung- normal 
 Sciatic nerve- normal 
 Brach. plex.- normal 
 Pancreas- normal 
 Gonads- ovaries (female) active follicule  
 Brain- normal 
 Spinal cord- normal 
 Eye- normal 
 Weight-87 g 
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Schubot Necropsy Report 
MRTFL 1460- Nymphicus hollandicus  
Necropsy done on 12 September 2014 by Dr. Gentry at 1:30PM 
History: Bird was previously inoculated with Parrot bornavirus-2 and was part of the 
Meloxicam/Celecoxib study; housed in isolation building 1044 in BSL2 room 6, Group 
1. End of study necropsy performed. Blood and urine was collected prior to euthanasia.   
 
Necropsy Report: 
 Air sacs- normal   
 Excellent fat stores 
 Keel score- 3 
 Crop-normal  
 PV- normal 
 V- normal 
 Intestines-normal 
 Cloaca- normal 
 Adrenals- normal 
 Liver-normal  
 Spleen- enlarged 
 Kidney-normal 
 Heart-1.1g  
 Lung- normal enlarged 
 Sciatic nerve- normal 
 Brach. plex.- normal 
 Pancreas- normal 
 Gonads- ovaries  (female) 
 Brain- normal 
 Spinal cord- normal 
 Eye- normal 
 Weight-93 
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Schubot Necropsy Report 
RAATX 10- Nymphicus hollandicus  
Necropsy done on 24 April 2014 by Dr. J. Jill Heatley at 2:30PM 
History: Bird was previously inoculated with Parrot bornavirus-2 and was part of the 
Meloxicam/Celecoxib study; housed in isolation building 1044 in BSL2 room 6, Group 
2. Bird was found at 9:00AM on 24 April 2014 with a drooping right wing. Bird was 
later found dead at 2:00PM. 
Necropsy Report: 
 Air sacs clear 
 Free fluid in left coelom; fluid was swabbed 
 At time of necropsy, distinct swelling was noted in the right wing 
 Keel score- 1 
 Crop- distended 
 PV- discolored; Slightly dilated 
 V - normal 
 Intestines- blackened 
 Cloaca- normal 
 Adrenals- normal 
 Liver- small white mass on liver 
 Spleen- normal 
 Kidney- pale with articulate pattern 
 Heart- mottling 
 Lung- normal 
 Sciatic nerve- normal 
 Brach. plex.- normal 
 Pancreas- very white/pale in color 
 Gonads- testes (young male) 
 Brain- normal 
 Spinal cord- normal 
 Eye- normal 
 Weight-76.0g 
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Schubot Necropsy Report 
MRTFL 2725- Nymphicus hollandicus  
Necropsy done on 08 June 2014 by Paulina Escandon at 9:30AM 
History: Bird was previously inoculated with Parrot bornavirus strain M24 and was part 
of the Meloxicam/Celecoxib study; housed in isolation building 1044 in BSL2 room 6, 
Group 2. Bird found with visible regurgitation, enlarged crop, and puffed up with head 
low/tilted at 9:00AM on the bottom of the cage. Also wobbly body and lethargic. Bird 
was euthanized by Paulina at 9:15AM. Blood was collected. 
Necropsy Report: 
 Air sacs clear 
 Dirty vent 
 Body condition score- low 2 
 Crop- enlarged; filled with seed 
 PV- enlarged 
 V- normal 
 Intestines- black portions; visible seeds 
 Cloaca- normal 
 Adrenals- normal 
 Liver- normal 
 Spleen- normal 
 Kidney- enlarged 
 Heart- normal 
 Lung- normal 
 Sciatic nerve- normal 
 Brach. plex.- normal 
 Pancreas- normal 
 Gonads- ovaries (female) 
 Brain- normal 
 Spinal cord- normal 
 Eye- normal 
 Weight- 117.6g 
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Schubot Necropsy Report 
MRTFL 1662- Nymphicus hollandicus  
Necropsy done on 09 September 2014 by Dr. Gentry at 1:30PM 
History: Bird was previously inoculated with Parrot bornavirus-2 and was part of the 
Meloxicam/Celecoxib study; housed in isolation building 1044 in BSL2 room 6, Group 
2. End of study necropsy performed. Blood and urine was collected prior to euthanasia.  
 
Necropsy Report: 
 Air sacs clear 
 Body condition score- 4 
 Crop-mild distended  
 PV- normal 
 V- normal 
 Intestines-normal 
 Cloaca- normal 
 Adrenals- normal 
 Liver-pale mottling  
 Spleen- normal 
 Kidney-normal 
 Heart-0.8g 1x1.6cm enlarged  
 Lung- normal 
 Sciatic nerve- normal 
 Brach. plex.- normal 
 Pancreas- normal 
 Gonads- testis (male) 
 Brain- normal 
 Spinal cord- normal 
 Eye- normal 
 Weight-93.6g 
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Schubot Necropsy Report 
TAMU254- Nymphicus hollandicus  
Necropsy done on 09 September 2014 by Dr. Gentry at 1:30PM 
History: Bird was previously inoculated with Parrot bornavirus-2 and was part of the 
Meloxicam/Celecoxib study; housed in isolation building 1044 in BSL2 room 6, Group 
2. End of study necropsy performed. Blood and urine was collected prior to euthanasia.  
 
Necropsy Report: 
 Air sacs clear 
 Body condition score- 3 of 5 
 Crop-mild distended 
 PV- dilated 
 V- normal 
 Intestines-mild distended 
 Cloaca- normal 
 Adrenals- normal 
 Liver-Green mottled 
 Spleen- normal 
 Kidney-normal 
 Heart- dilated 1.58g slightly enlarge  
 Lung- normal 
 Sciatic nerve- normal 
 Brach. plex.- normal 
 Pancreas- normal 
 Gonads- not recorded 
 Brain- normal 
 Spinal cord- normal 
 Eye- normal 
 Weight- 98.5g 
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Schubot Necropsy Report 
CWI 691- Nymphicus hollandicus  
Necropsy done on 09 September 2014 by Dr. Gentry at 1:30PM 
History: Bird was previously inoculated with Parrot bornavirus-2 and was part of the 
Meloxicam/Celecoxib study; housed in isolation building 1044 in BSL2 room 6, Group 
2. End of study necropsy performed. Blood and urine was collected prior to euthanasia.  
 
Necropsy Report: 
 Air sacs clear 
 Body condition score- 4 of 5 
 Crop-normal  
 PV- normal 
 V- normal 
 Intestines-pale GI tract 
 Cloaca- normal 
 Adrenals- normal 
 Liver-slight mottling  
 Spleen- normal 
 Kidney-normal 
 Heart-0.7g normal 
 Lung- normal 
 Sciatic nerve- normal 
 Brach. plex.- normal 
 Pancreas- normal 
 Gonads- testis (male) 
 Brain- normal 
 Spinal cord- normal 
 Eye- normal 
 Weight-106.5g 
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Schubot Necropsy Report 
RAATX 210- Nymphicus hollandicus  
Necropsy done on 09 September 2014 by Dr. Gentry at 1:30PM 
History: Bird was previously inoculated with Parrot bornavirus strain-2 and was part of 
the Meloxicam/Celecoxib study; housed in isolation building 1044 in BSL2 room 6, 
Group 2. End of study necropsy performed. Blood and urine was collected prior to 
euthanasia.  
Necropsy Report: 
 Air sacs clear 
 Dirty vent 
 Body condition score- 2 
 Crop- undigested seed 
 PV- dilated, undigested seed 
 V- undigested seed 
 Intestines- undigested seed 
 Cloaca- normal 
 Adrenals- normal 
 Liver- normal 
 Spleen- normal 
 Kidney-normal 
 Heart- dilated 1.2x1.7cm slightly enlarge 
 Lung- normal 
 Sciatic nerve- normal 
 Brach. plex.- normal 
 Pancreas- normal 
 Gonads- testis (male) 
 Brain- normal 
 Spinal cord- normal 
 Eye- normal 
 Weight- 85g 
 72 
 
 
Schubot Necropsy Report 
TAMU229- Nymphicus hollandicus  
Necropsy done on 09 September 2014 by Dr. Gentry at 1:30PM 
History: Bird was previously inoculated with Parrot bornavirus-2 and was part of the 
Meloxicam/Celecoxib study; housed in isolation building 1044 in BSL2 room 6, Group 
2. End of study necropsy performed. Blood and urine was collected prior to euthanasia.  
 
Necropsy Report: 
 Air sacs clear 
 Body condition score- 4 of 5 
 Crop-mild distended with seed 
 PV- mild dilated 
 V- normal 
 Intestines-normal 
 Cloaca- normal 
 Adrenals- normal 
 Liver-pale mottling  
 Spleen- normal 
 Kidney-normal 
 Heart- normal  
 Lung- normal 
 Sciatic nerve- normal 
 Brach. plex.- normal 
 Pancreas- normal 
 Gonads- ovaries (Female) 
 Brain- normal 
 Spinal cord- normal 
 Eye- normal 
 Weight-101g 
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 Schubot Necropsy Report 
TAMU221- Nymphicus hollandicus  
Necropsy done on 09 September 2014 by Dr. Gentry at 1:30PM 
History: Bird was previously inoculated Parrot bornavirus-2 and was part of the 
Meloxicam/Celecoxib study; housed in isolation building 1044 in BSL2 room 6, Group 
2. End of study necropsy performed. Blood and urine was collected prior to euthanasia.  
 
Necropsy Report: 
 Air sacs- not clear   
 Body condition score- 3 
 Crop-mild distention with undigested seed  
 PV- mild dilation 
 V- normal 
 Intestines-normal 
 Cloaca- normal 
 Adrenals- normal 
 Liver-normal  
 Spleen- normal 
 Kidney-normal 
 Heart-0.7g normal 
 Lung- normal 
 Sciatic nerve- normal 
 Brach. plex.- normal 
 Pancreas- normal 
 Gonads- testis (male) 
 Brain- normal 
 Spinal cord- normal 
 Eye- normal 
 Weight-94.6g 
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Schubot Necropsy Report 
TAMU261- Nymphicus hollandicus  
Necropsy done on 09 September 2014 by Dr. Gentry at 1:30PM 
History: Bird was previously inoculated with Parrot bornavirus-2 and was part of the 
Meloxicam/Celecoxib study; housed in isolation building 1044 in BSL2 room 6, Group 
2. End of study necropsy performed. Blood and urine was collected prior to euthanasia.  
 
Necropsy Report: 
 Air sacs- not clear   
 Body condition score- 3 of 5 
 Crop-normal  
 PV- mild dilation with seed 
 V- normal 
 Intestines-normal 
 Cloaca- normal 
 Adrenals- normal 
 Liver-pale yellow modeling suspect hepatic lipidosis 
 Spleen- normal 
 Kidney-normal 
 Heart-0.5g normal 
 Lung- normal 
 Sciatic nerve- normal 
 Brach. plex.- normal 
 Pancreas- normal 
 Gonads- ovaries (female) 
 Brain- normal 
 Spinal cord- normal 
 Eye- normal 
 Weight-107.5g 
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Schubot Necropsy Report 
*TAMU 204- Nymphicus hollandicus  
Necropsy done on 28 April 2014 by Dr. J. Jill Heatley at 9:00AM 
History: Bird was previously inoculated with Parrot bornavirus-2 and was part of the 
Meloxicam/Celecoxib study; housed in isolation building 1044 in BSL2 room 6, Group 
3. Bird was found dead at 8:30AM on the bottom of the cage. 
 
Necropsy Report: 
 Air sacs clear 
 BCS- 2 of 5 
 Crop- distended and attached to pectoral muscle 
 PV- enlarged; black surrounding area 
 V - normal 
 Intestines- blackened 
 Cloaca- normal 
 Adrenals- normal 
 Liver- normal 
 Spleen- normal 
 Kidney- mottled 
 Heart- normal 
 Lung- normal 
 Sciatic nerve- normal 
 Brach. plex.- normal 
 Pancreas- normal 
 Gonads- ovaries (inactive  female) 
 Brain- normal 
 Spinal cord- normal 
 Eye- normal 
 Weight- 97.0g  
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Schubot Necropsy Report 
*MRTFL 2441- Nymphicus hollandicus  
Necropsy done on 03 May 2014 by Jeann Leal and Paulina Escandon at 11:15AM 
History: Bird was previously inoculated with Parrot bornavirus-2 and was part of the 
Meloxicam/Celecoxib study; housed in isolation building 1044 in BSL2 room 6, Group 
2. Bird found perching but extremely lethargic with head tilted, body wobbly, and eyes 
closed. Bird was euthanized by Dr. Heatley at 11:00AM. Blood was collected from right 
jugular. 
Necropsy Report: 
 Air sacs clear 
 Body condition score- 3 of 5 
 Crop- normal; digestion visible 
 PV- slightly dilated (pale) 
 V - normal 
 Intestines- normal 
 Cloaca- normal 
 Adrenals- normal 
 Liver- normal 
 Spleen- normal 
 Kidney- normal 
 Heart- normal 
 Lung- normal 
 Sciatic nerve- normal 
 Brach. plex.- normal 
 Pancreas- normal 
 Gonads- not identified 
 Brain- normal 
 Spinal cord- normal 
 Eye- normal 
 Weight- 83.0g 
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Schubot Necropsy Report 
*TAMU 241- Nymphicus hollandicus  
Necropsy done on 05 May 2014 by Paulina Escandon 
History: Bird was previously inoculated with Parrot  bornavirus-2 and was part of the 
Meloxicam/Celecoxib study; housed in isolation building 1044 in BSL2 room 6, Group 
3. Bird found perching but extremely lethargic with head tilted, body wobbly, and eyes 
closed. Bird was euthanized by Paulina. Blood was collected. 
 
Necropsy Report: 
 Air sacs clear 
 Body condition score- 2 of 3 
 Crop- normal 
 PV- slightly enlarged 
 V - normal 
 Intestines- great amount of undigested seed 
 Cloaca- normal 
 Adrenals- normal 
 Liver- multifocal yellow areas on surface 
 Spleen- normal 
 Kidney- normal 
 Heart- normal 
 Lung- normal 
 Sciatic nerve- normal 
 Brach. plex.- normal 
 Pancreas- pale 
 Gonads- testes (male) 
 Brain- normal 
 Spinal cord- normal 
 Eye- normal 
 Weight- 74.5g 
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Schubot Necropsy Report 
*CWI 196- Nymphicus hollandicus  
Necropsy done on 03 June 2014 by Paulina Escandon 
History: Bird was previously inoculated with Parrot bornavirus-2 and was part of the 
Meloxicam/Celecoxib study; housed in isolation building 1044 in BSL2 room 6, Group 
2. Bird found lethargic, wobbly body, head tilted down, and eyes closed. Bird had visible 
enlarged crop and feces was noted to be dark in color. Bird was euthanized by Paulina. 
Blood was collected. 
Necropsy Report: 
 Air sacs clear 
 Body condition score- 1 
 Crop- enlarged 
 PV- discoloration 
 V- discoloration; black on inside upon opening 
 Intestines- black portions 
 Cloaca- normal 
 Adrenals- normal 
 Liver- discoloration 
 Spleen- very small in size 
 Kidney- normal 
 Heart- normal 
 Lung- normal 
 Sciatic nerve- normal 
 Brach. plex.- normal 
 Pancreas- discoloration 
 Gonads- testes (male) 
 Brain- normal 
 Spinal cord- normal 
 Eye- normal 
 Weight- 63.6g 
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Schubot Necropsy Report 
TAMU265- Nymphicus hollandicus  
Necropsy done on 08 September 2014 by Dr. Gentry at 1:30PM 
History: Bird was previously inoculated with Parrot bornavirus-2 and was part of the 
Meloxicam/Celecoxib study; housed in isolation building 1044 in BSL2 room 6, Group 
3. End of study necropsy performed. Blood and urine was collected prior to euthanasia.  
 
Necropsy Report: 
 Air sacs clear 
 Dirty vent 
 Keel score- 4 
 Crop- normal 
 PV- normal 
 V- normal 
 Intestines- normal 
 Cloaca- normal 
 Adrenals- normal 
 Liver- normal 
 Spleen- normal 
 Kidney-normal 
 Heart- 0.9g slightly enlarged 
 Lung- normal 
 Sciatic nerve- normal 
 Brach. plex.- normal 
 Pancreas- normal 
 Gonads- ovaries  (female) 
 Brain- normal 
 Spinal cord- normal 
 Eye- normal 
 Weight- 115g 
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Schubot Necropsy Report 
TAMU215- Nymphicus hollandicus  
Necropsy done on 08 September 2014 by Dr. Gentry at 1:30PM 
History: Bird was previously inoculated with Parrot bornavirus-2 and was part of the 
Meloxicam/Celecoxib study; housed in isolation building 1044 in BSL2 room 6, Group 
3. End of study necropsy performed. Blood and urine was collected prior to euthanasia.  
 
Necropsy Report: 
 Air sacs clear 
 Body condition score- 4 of 5 
 Crop- normal 
 PV- normal 
 V- Contents was bright green 
 Intestines- normal 
 Cloaca- normal 
 Adrenals- normal 
 Liver- normal 
 Spleen- normal 
 Kidney-normal 
 Heart- dilated 0.4g slightly enlarge 
 Lung- normal 
 Sciatic nerve- normal 
 Brach. plex.- normal 
 Pancreas- normal 
 Gonads- ovaries (female) 
 Brain- normal 
 Spinal cord- normal 
 Eye- normal 
 Weight- 93.8g 
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Schubot Necropsy Report 
TAMU247- Nymphicus hollandicus  
Necropsy done on 08 September 2014 by Dr. Gentry at 1:30PM 
History: Bird was previously inoculated with Parrot bornavirus-2 and was part of the 
Meloxicam/Celecoxib study; housed in isolation building 1044 in BSL2 room 6, Group 
3. End of study necropsy performed. Blood and urine was collected prior to euthanasia.  
 
Necropsy Report: 
 Air sacs clear 
 Body condition score- 3 of 5 
 Crop- normal 
 PV- normal 
 V- normal 
 Intestines- normal 
 Cloaca- normal 
 Adrenals- normal 
 Liver- normal 
 Spleen- normal 
 Kidney-normal 
 Heart- dilated 1.58g slightly enlarge **** 
 Lung- normal 
 Sciatic nerve- normal 
 Brach. plex.- normal 
 Pancreas- normal 
 Gonads- immature ovaries (female) 
 Brain- normal 
 Spinal cord- normal 
 Eye- normal 
 Weight- 93.5g 
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Schubot Necropsy Report 
TAMU297- Nymphicus hollandicus  
Necropsy done on 08 September 2014 by Dr. Gentry at 1:30PM 
History: Bird was previously inoculated with Parrot bornavirus-2 and was part of the 
Meloxicam/Celecoxib study; housed in isolation building 1044 in BSL2 room 6, Group 
3. End of study necropsy performed. Blood and urine was collected prior to euthanasia.  
 
Necropsy Report: 
 Air sacs clear 
 Dirty vent 
 Body condition score- 3 of 5 
 Crop- normal 
 PV- normal 
 V- normal 
 Intestines- normal 
 Cloaca- normal 
 Adrenals- normal 
 Liver- normal 
 Spleen- normal 
 Kidney-normal 
 Heart- 0.6g slightly enlarge 
 Lung- normal 
 Sciatic nerve- normal 
 Brach. plex.- normal 
 Pancreas- normal 
 Gonads- testis (male) 
 Brain- normal 
 Spinal cord- normal 
 Eye- normal 
 Weight- 85.9g 
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Schubot Necropsy Report 
TAMU279- Nymphicus hollandicus  
Necropsy done on 08 September 2014 by Dr. Gentry at 1:30PM 
History: Bird was previously inoculated with Parrot bornavirus-2 and was part of the 
Meloxicam/Celecoxib study; housed in isolation building 1044 in BSL2 room 6, Group 
3. End of study necropsy performed. Blood and urine was collected prior to euthanasia.  
 
Necropsy Report: 
 Air sacs clear 
 Dirty vent 
 Body condition score- 4 of 5 
 Crop- normal 
 PV- Moderate amount of fluid 
 V- moderate amount of fluis 
 Intestines- normal 
 Cloaca- normal 
 Adrenals- normal 
 Liver- normal 
 Spleen- normal 
 Kidney-normal 
 Heart- 0.8g slightly enlarge 
 Lung- normal 
 Sciatic nerve- normal 
 Brach. plex.- normal 
 Pancreas- normal 
 Gonads- testis (male) 
 Brain- normal 
 Spinal cord- normal 
 Eye- normal 
 Weight- 95g 
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APPENDIX D 
PROTOCOLS 
Cell Culture 
Cells require an appropriate temperature of 37˚C and 5% CO2 mixture for growth 
and maintenance, which can be accomplished with a cell incubator. In addition to 
temperature and gas conditions, different cell cultures require different media that 
contains factors for cell growth and promotion. The precise medium will vary between 
cell lines but for the most part media requires having a specific pH, glucose 
concentration, and growth factor supplements usually derived from animal blood serum. 
To prevent for any bacterial or fungal contamination there are additional supplements 
such as antimycotic, and, actinomycin D, penicillin streptomycine, that can also be 
added. 
(A) Isolating primary cell lines. 
The primary cell cultures that were established in these protocol were isolated 
from the eggs of duck, quaker parrots, and zebra finches. 
Harvesting duck embryo fibroblast cells from duck eggs. 
1. 20 fertile Mallard duck eggs were purchased from Metzer Farm in California.
2. Prior to arrival of the eggs, the egg incubator was cleaned, turned on, and filled
with distilled water in order to allow temperature to reach 37.5˚C and 
approximately 60% humidity. 
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3. Immediately after delivery, the fertile Mallard eggs were numbered 1-20 and 
inserted in the incubator’s rotating platform in automatic speed setting for 
approximately 12 days. 
4. On the 12th day, the eggs are candled using a flashlight to observe embryo 
development.  
5. If the eggs are ready to be harvested they will be sprayed with 70% ethanol and 
chilled at 4˚C refrigerator for one hour. (This process humanely euthanizes the 
embryo) 
6. After being chilled for one hour, the eggs will be sprayed again with 70% 
ethanol. 
7. The egg tops (the area with the big end of the shell) are removed with sterile 
scissors under a biological safety cabinet. Using the sterile scissors, tap the shell 
to create a hole and then use the pointy end to cut around the egg to remove the 
tops. 
8. The embryos were then extracted using sterile forceps and placed into sterile 
petri dishes. The eggs were then decapitated using sterile blades and the heads 
were placed in 1.5mL sterile vials numbered 1-20 respective to each egg. Heads 
were then tested using reverse transcriptase polymerase chain reaction (PCR), as 
a control to confirm the absence of parrot bornavirus (PaBV) within the embryo. 
9. The embryos then had their limbs and internal organs removed with a sterile 
blade. 
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10. Two embryos were then eviscerated and placed into a trypsinizing glass flask 
containing a magnetic stir bar. 
11. To remove red blood cells, add 25mL of PBS, wash by swirling for a minute, 
then remove PBS without discarding the embryo body parts. (This process is 
repeated two more times.) 
12. Add 25mL of trypsin-EDTA 0.05% at room temperature to a trypsinizing flask 
and stir it at room temperature for 6 minutes. NOTE: You can use 15mL of 
trypsin-EDTA 0.05% if the amount and size embryo is greatly decreased.  
13. Decant the trypsin from the trypsinizing flask through 8 layers of sterile 
cheesecloth into a beaker containing complete medium (DMEM with 5%FBS 
and 1%Pen Strep). The beaker is placed on ice and the cheesecloth is 
presaturated with complete medium in the central region only. (The medium 
stops the enzymatic digestion performed by trypsin.) 
14. Repeat steps 12, 13 until the remaining embryo tissue is no longer visible.  
15. The contents of the beaker were then separated into 50mL centrifuge tubes and 
spun at a 2,000 rpm for 10 minutes at 10ºC. 
16. The supernatant is then removed and the cell pellet is resuspended in 50% FBS 
and 50% complete medium containing 20% dimethyl sulfoxide (DMSO). 
Amount of solution will depend on the cell to cryogenic vial contents wanted. 
17. Solution will then be divided into 1mL cryogenic vials and slow freeze using 
Nalgene Freezing container at -89ºC. (Cryogenic vials are labeled with Metzer 
Farm, Clean DEF cell, mm/dd/yyyy, # of egg.) 
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Harvest Quaker parrot embryo fibroblast cells from Quaker parrots eggs 
The quaker parrot eggs were collected from our Schubot aviary. Quaker eggs 
were candled every day until two days prior to hatching. The rest of the process was 
exactly the same as the duck egg protocol above. Cryogenic vials are labeled with 
Schubot, Clean QEF cells, mm/dd/yyyy, # of egg. 
Harvest Zebra finch embryo fibroblast cells from Zebra finch eggs 
The zebra finch eggs were donated from one of our veterinary pathobiology 
professors. Zebra finch eggs are much smaller than quaker eggs so the process had to be 
modified to obtain the maximum amount of zebra finch embryo fibroblast cells.  
1. Zebra finch eggs were candled on a daily basis until two days prior to hatching 
(when the light from the flashlight isn’t visible thru the egg).  
2. If the eggs are ready to be harvested they will be sprayed with 70% ethanol and 
chilled at 4˚C refrigerator for one hour. (This process humanely euthanizes the 
embryo) 
3. After being chilled for one hour, the eggs will be sprayed again with 70% 
ethanol. 
4. The egg tops (the area with the big end of the shell) are removed with sterile 
scissors under a biological safety cabinet. Using the sterile scissors, tap the shell 
to create a hole and then use the pointy end to cut around the egg to remove the 
tops. 
5. The embryos were then extracted using sterile forceps and placed into sterile 
petri dishes. The eggs were then decapitated using sterile blades and the heads 
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were placed in 1.5mL sterile vials numbered 1-3 respective to each egg. Heads 
were then tested using reverse transcriptase polymerase chain reaction (PCR), as 
a control to confirm the absence of parrot bornavirus (PaBV) within the embryo. 
6. Each embryo was then eviscerated and its limbs and organs were removed if they 
were visible. 
7. The embryo was then rinsed with PBS three times using a syringe to remove all 
red blood cells.  
8. The embryo was exposed to 2mL of trypsin in a 15mL conical vial and swirled 
by hand for 3 minutes. 
9. To stop the enzymatic digestion of trypsin, 3mL of complete medium were added 
to the 15mL conical vial. 
18. Centrifuge the 15mL conical vial at 1,000 rpm at 10ºC for 10 minutes. 
10. Remove the supernatant and resuspended the cell pellet with complete medium 
and inserted in a 25mL volumetric flask. The 25mL volumetric flask is then 
placed in a cell incubator at 37˚C, 5% CO2, and with 95% humidity. 
11. Incubation of zebra finch embryo fibroblast cells continued until the flask 
reached 90% cell confluence, then the cells in the flask were divided into two 
25mL flasks. 
12. Step 11 was repeated 4 more times for propagation of zebra finch embryo 
fibroblast cells. (This process is described on section (B) of cell culture 
protocols) 
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13. Zebra finch embryo fibroblast cells from each of the ten 25mL flasks were 
detached from the 25mL flask floor by using 0.25% trypsin-EDTA. 
a. Use 1.5mL of 0.25% trypsin-EDTA into a 25mL flask and wash (by 
swirling trypsin on flask floor) for 2 seconds. 
b. Immediately after wash remove the 1.5mL of 0.25% trypsin-EDTA and 
discard in beaker with 10% bleach solution. NOTE: This step removes 
any excess complete media and begins the enzymatic digestion of trypsin. 
14. 0.5mL of trypsin then is added and swirled until the complete flask floor is 
covered. 
15. The 25mL flask is then placed in the clean cell culture incubator for 2 minutes or 
until cells are seen detached by using a cell culture microscope. 
16. To stop trypsin’s enzymatic digestion, add 2mL of complete media solution and 
gently agitate flask with your hand to loosen any adhered cells. NOTE: steps 13-
16 are repeated with the rest of the nine 25mL flask containing zebra finch 
embryo fibroblast cells. 
17. Combine the 2mL of complete media and zebra finch embryo fibroblast cells 
from each of the 10 flask into one 25mL flask and swirl. 
18. Pour the 25mL of complete media and zebra finch embryo fibroblast cells into a 
50mL conical tube. 
19. Centrifuged solution at 1,000 rpm and 10ºC for 10 minutes in an Allegra X-15 
centrifuge. NOTE: Make sure to balance centrifuge with another 50mL conical 
tube containing 25mL of tap water. 
 103 
 
20. Remove the supernatant from the conical tube and discard it in the beaker with 
10% bleach. 
21. To resuspend the pelleted cells, add 20mL of freezing media solution and mix 
slowly with the electronic pipettor.  
22. In 20 cryogenic vials add 1mL of zebra finch embryo fibroblast cells and 
freezing media solution and slow frozen using Nalgene Freezing container at -
89ºC. (Cryogenic vials are labeled with Dr. Payne, Clean Zebra Finch EF cells, 
mm/dd/yyyy, #of egg.) NOTE: To slow freeze leave cryogenic vials for at least 
5 days in the Nalgene Freezing container at -89ºC. 
 
(B) Propagation of cell culture line. 
Propagation of a cell culture line can be from a previously harvested cell culture 
line from an egg that has been frozen multiple times with freezing media (50% FBS and 
50% complete medium containing 20% dimethyl sulfoxide (DMSO) in a Nalgene 
Freezing container at -89C. Growing cell culture lines by the process of passaging cells 
results in the increase of cell culture line density which allows for further research 
studies or creation of a cell line stock. Passaging cells involves growing a cell culture 
line and transferring a small portion of the cells to another flask after a 80-90% 
confluence, to prolong high cell density. The propagation process is similar for different 
species’ cell lines, however, it differs in the amount of time it takes for each cell line to 
reach optimal confluence which is 80-90%. 
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Propagation of duck embryo fibroblast (DEF) cells from DEF cells vial stock 
To propagate a DEF cell line, we will use one cryogenic vial of previously frozen 
DEF cells. This cryogenic vial could have come from a primary line or it could have 
previously been propagated. This process will be divided into four parts. NOTE: These 
duck embryo fibroblast cells are not experimentally immortalized, therefore, this may 
result in a decline in the quality and quantity of the cell line after a number of 
propagations. 
1. Prepare cell culture cabinet (BSL II cabinet) with an electronic pipettor, complete 
media solution (DMEM media that contains 10% fetal bovine serum (FBS) and 
1% penicillin streptomycin), (manufacturer: Life technologies) and a discard 
beaker containing 10% bleach solution. NOTE: DMEM media needs to be at 
room temperature prior to use to prevent rupturing of cells. 
2. Insert 1 vial containing 1mL of clean DEF cells into a clean latex glove and tie a 
knot to minimize the amount of water exposure.  
3. Quick thaw the vial in a 37ºC water bath by swirling the vial in water just until 
thawed to ensure a higher proportion of cells survive. This will take about 2-3 
minutes.  
4. Remove vial from clean latex glove and spray vial with 10% bleach before 
placing it in cell culture cabinet. 
5. Add 10mL of complete media solution into a 15mL conical tube. 
6. Pour the 1mL of clean DEF cells into the 15mL conical tube with 10mL 
complete media solution. 
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7. Solution will then be centrifuged at 1,000 rpm and 10ºC for 10 minutes in an 
Allegra X-15 centrifuge. NOTE: Make sure to balance centrifuge with another 
15mL conical tube containing 11mL of tap water. 
8. Remove the supernatant from the conical tube and discard it in the beaker with 
10% bleach. 
9. To resuspend the pelleted cells, add 5mL of complete media solution and mix 
slowly with the electronic pipettor.  
10. Finally, add the 5mL of resuspended cells into a 25mL flask and incubate in a 
clean cell culture incubator at 37ºC and 5% CO2. 
11. Check cells daily for about 3-4 days or until cell confluence is 80-90%. When 
25mL flask has an 80-90% cell confluence, the cells will be passaged into a 
75mL flask. NOTE: Cell confluence progression changes depending on cell type 
or amount of cells per unit square. 
 
Part II 
1. To begin separating cells from the 25mL flask into a 75mL flask, the 5 mL of 
complete media are removed and discard in a beaker with 10% bleach 
solution. 
2. Cells are then detached from the 25mL flask floor by using 0.25% trypsin-
EDTA. 
a. Use 1.5mL of 0.25% trypsin-EDTA to wash (by swirling trypsin on 
flask floor) for 2 seconds. 
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b. Immediately after wash remove the 1.5mL of 0.25% trypsin-EDTA 
and discard in beaker with 10% bleach solution. NOTE: This step 
removes any excess complete media and begins the enzymatic 
digestion of trypsin. 
3. 0.5mL of trypsin then is added and swirled until the complete flask floor is 
covered. 
4. The 25mL flask is then placed in the clean cell culture incubator for 2 
minutes or until cells are seen detached by using a cell culture microscope. 
5. To stop trypsin’s enzymatic digestion, add 15mL of complete media solution 
and gently agitate flask with your hand to loosen any adhered cells. 
6. Transfer the mixture of 15mL complete media with cells to a 75mL flask and 
incubate in a clean cell culture incubator until 80-90% cell confluence 
(approximately 3-4 days). 
Part III 
When the 75mL flask reaches 80-90% confluence, DEF cells are passaged into two 
75mL flask. The following steps are performed to passage cells into two 75mL flasks. 
1. Removed the 15mL of complete media and discarded into a beaker with 10% 
bleach solution. NOTE: If cells begin to over grow on bottom of flask you may 
lose some cells when removing the 15mL of complete media. That is why it is 
best to separate before 100% confluence.  
2. Cells are then detached from the 75mL flask floor by using 0.25% trypsin-
EDTA. 
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a. Use 3.0mL of 0.25% trypsin-EDTA to wash (by swirling trypsin on flask 
floor) for 2 seconds. 
b. Immediately after wash remove the 3.0mL of 0.25% trypsin-EDTA and 
discard in beaker with 10% bleach solution. NOTE: This step removes 
any excess complete media and begins the enzymatic digestion of trypsin. 
3. 1.5mL of trypsin is then added and swirled until the complete flask floor is 
covered. 
4. The 75 mL flask is then placed in the clean cell culture incubator for 2 minutes or 
until cells are seen detached by using a cell culture microscope. 
5. To stop trypsin’s enzymatic digestion, add 10mL of complete media solution and 
gently agitate flask with your hand to loosen any adhered cells. 
6. Add 5mL of complete media with cells to each 75mL flask and then add 10mL of 
fresh complete media to each 75mL flask. (Making a total volume of 15mL per 
flask) NOTE: Original 75mL flask can be reused once. 
7. Incubate both 75mL flasks in clean cell culture incubator until 80-90% cell 
confluence (approximately 3-4 days). 
Part III is repeated two more times for each of the 75mL flask, concluding with 
eight 75mL flask of 80-90% cell confluence. 
Part IV 
1. The 15mL of complete media are removed from each of the eight 75mL flasks 
and discarded in a beaker with 10% bleach solution.  
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2. Cells are then detached from the 75mL flask floor by using 0.25% trypsin-
EDTA. 
a. Use 3.0mL of 0.25% trypsin-EDTA to wash (by swirling trypsin on flask 
floor) for 2 seconds. 
b. Immediately after wash remove the 3.0mL of 0.25% trypsin-EDTA and 
discard in beaker with 10% bleach solution. NOTE: This step removes 
any excess complete media and begins the enzymatic digestion of trypsin. 
3. 1.5mL of trypsin is then added and swirled until the complete flask floor is 
covered. 
4. The flasks are then placed in the clean cell culture incubator for 2 minutes or 
until cells are seen detached by using a cell culture microscope. 
5. To stop trypsin’s enzymatic digestion, add 5mL of complete media solution and 
gently agitate flask with your hand to loosen any adhered cells. 
6. The 5mL of each of the 75mL flask were then combined in a 50mL conical vial. 
7. The 50mL conical vial was then centrifuged for 10 minutes at 1,000 rpm and 
10ºC in an Allegra X-15 centrifuge. 
8. The supernatant is then removed and the cell pellet is resuspended in 50% FBS 
and 50% complete medium containing 20% dimethyl sulfoxide (DMSO). 
Amount of solution will depend on the amount of cells to vial ratio wanted. 
NOTE:  One 75mL flask approximately makes two-three 1mL cryogenic vials  
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9. The solution will then be divided into 1mL cryogenic vials and slowly frozen in a 
Nalgene Freezing container at -89ºC. (Cryogenic vials are labeled with Clean 
DEF cell, mm/dd/yyyy, vial stock) 
Harvest muscle Quail cells from muscle Quail cell vial stock 
The process was exactly the same as the propagation of duck embryo fibroblast 
(DEF) cells from the DEF cells vial stock depicted above. Muscle quail cell lines have 
been shown to grow at a higher rate than duck embryonic fibroblast cells, meaning this 
will change the times for each of the incubation periods. NOTE: Checking on our 
flask’s % confluence on a daily basis will help anticipate the timing in which to divide 
the flask for propagation. Cryogenic vials are labeled with Schubot, Clean mQuail cells, 
mm/dd/yyyy. 
Harvest Quaker embryo fibroblast cells from Quaker vial stock 
The process was exactly the same as the propagation of duck embryo fibroblast 
(DEF) cells from the DEF cells vial stock depicted above. Cryogenic vials are labeled 
with Schubot, Clean QEF cells, mm/dd/yyyy.  
Harvest Zebra finch embryo fibroblast cells from Zebra vial stock 
The process was exactly the same as the propagation of duck embryo fibroblast (DEF) 
cells from the DEF cells vial stock depicted above. Cryogenic vials are labeled with 
Schubot, Clean ZFEF cells, mm/dd/yyyy.  
 
 
 
 110 
 
 C) Infect cell culture line from viral stock 
Infecting cell culture lines is a useful application of cell cultures. Studying 
infected cell cultures is essential to better understand a virus’ lifecycle, possible viral 
treatments/vaccinations, and how a virus is transmitted.  
Infecting DEF cell culture line from parrot bornavirus genotype 4 (PaBV-4) viral 
stock. 
To infect DEF cell culture line there are two parts. 1) A cell line has to be 
cultured and allowed to be grown into 50-60% confluence. 2) Infected DEF cell line is 
used to infect growing DEF cells. Infected DEF cells can be propagated to create a viral 
stock for future experiments while a portion of the infected cells are tested for parrot 
bornavirus detection, in order to confirm viral presence. Parrot bornavirus have been 
shown to replicate within the cell’s nucleus. Parrot bornavirus method of transmission is 
by cell to cell contact. NOTE: Utilize two distinct cell culture incubators to prevent 
contamination of uninfected cells with virus: The “clean” cell culture incubator will 
house uninfected cells while the “dirty” cell culture incubator will house infected cells. 
When working in the cell culture cabinet, first work with uninfected cell culture prior to 
working with infected cell culture to prevent viral cross-contamination. 
Part I 
1.  Prepare cell culture cabinet (BSL II cabinet) with an electronic pipettor, 
complete media solution (DMEM media that contains 10% fetal bovine serum 
and 1% penicillin streptomycin) (manufacture: Life technologies) and a discard 
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beaker containing 10% bleach solution. NOTE: DMEM media needs to be at 
room temperature prior to use to prevent rupturing of cells. 
2. Insert 1 vial of clean DEF cells into a clean latex glove and tie a knot to minimize 
the amount of water exposure.  
3. Quick thaw the vial in a 37ºC water bath by swirling the vial in water just until 
thawed to ensure a higher proportion of cells survive. This will take about 2-3 
minutes. 
4. Remove vial from clean latex glove and spray vial with 10% bleach before 
placing it in cell culture cabinet. 
5. Add 10mL of complete media solution into a 15mL conical tube. 
6. Pour cryogenic vial containing 1mL of uninfected DEF cells into the 15mL 
conical tube with 10mL complete media solution. 
7. Solution will then be centrifuged at 1000 rpm and 10ºC for 10 minutes in an 
Allegra X-15 centrifuge. NOTE: Make sure to balance centrifuge with another 
15mL conical tube containing 11mL of tap water. 
8. Remove the supernatant from the conical tube and discard in beaker with 10% 
bleach. 
9. To resuspend the pelleted cells, add 5mL of complete media solution and mix 
slowly with the electronic pipettor.  
10. Finally, add the 5mL of resuspended cells into one 25mL flasks and incubate in a 
clean cell culture incubator at 37ºC and 5% CO2. 
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11. Check cells daily for about 3-4 days or until cell confluence is 50-60%. When 
25mL flask has a 50-60% cell confluence, the cells will be infected with PaBV-4 
DEF cells.  
Part II 
1. Insert 1 cryogenic vial containing 1mL of infected DEF cells into a clean latex 
glove and tie a knot to minimize the amount of water exposure.  
2. Quick thaw the vial in a 37ºC water bath by swirling the vial in water just until 
thawed to ensure a higher proportion of cells survive. This will take about 2-3 
minutes  
3. Remove cryogenic vial from clean latex glove and spray vial with 10% bleach 
before placing it in cell culture cabinet. 
4. Add 10mL of complete media solution into a 15mL conical tube. 
5. Pour the 1mL of infected DEF cells into the 15mL conical tube with 10mL 
complete media solution. 
6. Solution will then be centrifuged at 1000 rpm and 10ºC for 10 minutes in an 
Allegra X-15 centrifuge. NOTE: Make sure to balance centrifuge with another 
15mL conical tube containing 11mL tap water. 
7. Remove the supernatant from the conical tube and discard in beaker with 10% 
bleach. 
8. To resuspend the pelleted cells, add 5mL of complete media solution and mix 
slowly with the electronic pipettor.  
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12. Finally, add the 5mL of resuspended cells into the 25mL flasks with uninfected
DEF cells and incubate in a “dirty” cell culture incubator at 37ºC and 5%CO2. 
13. Check cells daily for about 3-4 days or until cell confluence is 80-90%. When
25mL flask has an 80-90% cell confluence, the cells will be passaged into one 
75mL flask for further propagation of infected cell culture line to create a viral 
cell culture stock. 
D) Diagnostic test for PaBV
Indirect immunocytochemistry assay (ICC) 
Indirect immunocytochemistry involves an unlabeled primary antibody which 
binds with an antigen and a labeled secondary antibody which binds with the primary 
antibody. Indirect immunocytochemistry is commonly used because of it higher 
sensitivity. This higher sensitivity is due to signal amplification caused by several 
secondary antibodies binding with different antigenic sites on the primary antibody. We 
used an secondary antibody labeled with an alkaline phosphatase enzyme. 
Prep- Materials: 
A) 0.02M Phosphate buffer solution (PBS)
1. Weigh out 35.49g of  0.5M Na2HPO4 and dissolve in 500mL of de-ionized
water. 
2. Weigh out 59.99g of 1M NaH2PO4 and dissolve in 500mL of deionized water.
3. Weigh out 116.88g of 4M NaCl and dissolve in 500mL of deionized water.
4. Mix 11.54 mL of 0.5M Na2HPO4 solution, 4.23mL of 1M NaH2PO4 solution,
37.5mL of 4M NaCl and add ultra pure water to make a total of 1,000mL 
 114 
 
NOTE:  Autoclave solution for lasting purposes. 
B) 2% paraformaldehyde solution in PBS 
1. Weigh out 1g paraformaldehyde powder (Sigma, St. Louis, MO) to 32 mL of 0.02M 
PBS. 
2. Add 12.5uL of 2M NaOH. (2M NaOH: 20mL NaOH into 80mL of deionized water) 
3. Heat to 60ºC (NOTE: make sure solution is in a sealed container), mix frequently 
until the paraformaldehyde goes into solution. (NOTE: this will happen quickly as soon 
as the suspension reaches 70 ºC) Allow the solution to cool to room temperature. 
4. Adjust pH to 7.4 using 0.1 M NaOH or 0.1M HCl, if needed. 
5. Adjust volume to 50 mL with PBS 
6. Filter and store away from light at 4ºC. 
Indirect immunocytochemistry assay protocol: 
1. Wash infected DEF cells 2 times for 5 minutes in 0.02M phosphate buffer solution 
(PBS). NOTE: wash by setting plate in bench rocker 
2. Fix for 10 minutes in 2% paraformaldehyde in 0.02M PBS. 
3. Wash 2 times for 5 minutes in 0.02M PBS.  
4. Permeabilize cells in 1% Triton X-100/0.02 M PBS for 10 minutes. 
5. Wash 3 times for 5 minutes each time in 0.03% Tween / 0.02M PBS. NOTE: Make 
sure to make a new batch of 0.03% Tween/PBS each time you do an 
immunocytochemistry assay. 
6. Blocking performed for 2 hours in 5% dried milk/ (0.03% Tween /PBS) 
115 
NOTE: Immunocytochemistry assay take approximately 6 hours. You can leave the 
blocking overnight in a humidified chamber if you can’t finish all at once. 
7. Incubate in a humidified chamber for 30 minutes at 37˚C with the primary antibody at
a 1:500 dilution in 1% dried milk/ (0.03% Tween/PBS) 
8. Wash 3 times for 5 minutes in 0.03% Tween/PBS.
9. Incubate in humidified chamber for 30 minutes at 37˚C with the secondary antibody
(AP- conjugated goat anti-macaw IgG) at a 1:500 dilution in 1% dried milk 
/(0.03%Tween/PBS). 
10. Wash 3 times for 5 minutes in 0.03% Tween/PBS.
11. In 50 mL tube add two Sigma FAST BCIP/NBT tablet into 20 mL ultrapure water,
then add 2 mL into each well. 
**Look for color change (blue-purple) on the bottom of the plate where cells are fixed** 
One-step TaqMan qRT-PCR 
One-step TaqMan RT-PCR reagents are designed to detect a specific RNA target 
by performing reverse transcription (RT) and polymerase chain reaction (PCR) 
amplification simultaneously. Reverse transcription is when an enzyme catalyzes the 
mRNA or RNA to generate its complementary DNA (cDNA). Reverse transcriptase in 
PCR is used to qualitatively detect gene expression of RNA viruses through the creation 
of the virus mRNA’s complementary DNA. Prior to using the One-step TaqMan RT-
PCR master mix reagent kit we had to extract the mRNA from our samples. To extract 
the mRNA we used the QIAamp Viral RNA Mini kit. This kit purifies the viral mRNA 
from tissue, cell, and cloacal swab samples. 
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(NOTE: for detailed information use QIAamp Viral RNA Mini Handbook 
manufacture: QIAGEN) 
RNA extraction procedures: 
1. Mix volume of Buffer AVL and carrier RNA-Buffer AVE depending on the amount 
of samples being extracted. For optimal results you will want 5.6µg of carrier RNA per 
sample. NOTE: QIAamp Viral RNA Mini Handbook has a table with the volume of 
Buffer AVL and carrier RNA-Buffer AVE depending on the amount of samples. Mix 
solution by rotating 5-6 times, do NOT use vortex. 
2. In a 1.5mL microcentrifuge tube add 560µL of Buffer AVL and carrier RNA-Buffer 
AVE mixture. 
3. Add 140µL of your sample in microcentrifuge and mix for 20seconds using vortex, 
making a homogeneous solution. 
4. Incubate at 21 °C (70 °F) for 10 minutes. 
5. Centrifuge the tubes for 30 seconds at 8,000-10,000 rpm to remove any drops from 
the inside of the lid. 
6. Add 560µL of ethanol (100% pure) to the sample and mix for 15 seconds using the 
vortex. 
7. Centrifuge the tubes for 30 seconds at 8,000-10,000 rpm to remove any drops from 
the inside of the lid. 
8. Insert QIAamp mini column filter and add 630µmL of the buffer AVL-carrier RNA, 
sample, and ethanol mixture into a 2mL microcentrifuge collection tube.  
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9. Centrifuge for 1 minute at 8,000 rpm, then place the QIAamp mini column filter into a 
new microcentrifuge and discard the liquid that has passed through the filter. NOTE: 
Repeat this step if there is a larger sample volume. 
10. Add 500µL of Buffer AW1 into QIAamp mini column filter and centrifuge for 1 
minute at 10,000 rpm, then place the QIAamp mini column filter into a new 
microcentrifuge and discard the liquid that has passed through the filter. 
11. Add 500µL of Buffer AW2 into QIAamp mini column filter and centrifuge for 3 
minutes at 14,000 rpm, then place the QIAamp mini column filter into a new 
microcentrifuge and discard the liquid that has passed through the filter.  
12. Centrifuge for 1 minute at 14,000 rpm, and then place the QIAamp mini column 
filter into a new microcentrifuge and discard the liquid that has passed through the filter. 
13. Add 60µL of Buffer AVE equilibrated to room temperature and let it rest for 1 
minute, then centrifuge at 10,000 rpm for 1 minute. NOTE: Buffer AVE elutes viral 
mRNA from the QIAamp mini column filter. 
One-step TaqMan RT-PCR procedures 
Materials needed: 
 PaBV matrix (M1) gene set, which contains: primer #1 and #2 (mix 18 µM 
of each primer together to yield a final concentration of 36µM) and 
Taqman probe # 3 at 10 µM.  
o  M1 primers- #1: (5'- GGTAATTGTTCCTGGATGG-3'), #2: (5'-
ACACCAATGTTCCGAAGACG-3'), and Taqman probe #3 (5’-
FAM-TCGATAACTG [Y]TCCCTTCCGGTC-BHQ-3’) 
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 PaBV Phosphoprotein (P2) set, which contains: primer #9 and #10 (mix 18
µM of each primer together to yield a final concentration of 36 µM) and 
Taqman probe #11 at 10 µM.  
o P2 primers- #9: (5’ AAGAAGAACCTCCATGATCTC 3’), #10: (5’-
AATGCCGAATAGTCATC- 3’), and Taqman probe #11: (5’-FAM-
TCGATAACTG [Y]TCCCTTCCGGTC-BHQ-3’) for the detection of 
PaBV  Phosphprotein  mRNA. 
 Taqman Fast virus master tough mix with ROX fluorescent dye. (Life
Technologies) 
 Ultrapure H2O
 Samples mRNA (NOTE: these samples are the samples that were
collected from the RNA extractions procedures described above) 
 24 well plate
NOTE: Mix Taqman fast virus 1-step master mix, ultrapure H2O, mRNA of viral 
samples, PCR primers, and taqman probe for the desired target using the following 
template. 
(This is per sample/well) 
a. Taqman fast virus master mix------------------------------------------ 6µL
b. Primer mix (for either M1 (#1/2) or P2 (#9/10) set) ---------------- 0.3µL
c. Probe (for either M1 (#3) or P2 (#11) set) ---------------------------- 0.3µL
d. Ultrapure H2O------------------------------------------------------------- 0.4µL
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 e. mRNA per sample-------------------------------------------------------- 5µL 
______________________________________________________________________ 
                                                                                                            Total= 12µL per well 
 
1. To test for 24 samples, mix enough solution for 27 samples, with the M1 primer and 
probes in a 1.5mL microtube. (Label microtube: M1 MASTER MIX) NOTE: Always 
prepare master mix for at least 3 extra samples. 
a. Taqman fast virus master mix------------------------------------------ 162µL 
 b. Primer mix (M1 (#1/2) set) --------------------------------------------- 8.1µL 
 c. Probe (M1 (#3) set) ------------------------------------------------------ 8.1µL 
 d. Ultrapure H2O------------------------------------------------------------- 10.8µL 
2. To test for 24 samples, mix enough solutions for 27 samples, with the P2 primer and 
probes in a 1.5mL microtube. (Label microtube: P2 MASTER MIX) NOTE: Always 
prepare master mix for at least 3 samples extra. 
a. Taqman fast virus master mix------------------------------------------ 162µL 
 b. Primer mix (P2 (#9/10) set) -------------------------------------------- 8.1µL 
 c. Probe (P2 (#11) set) ----------------------------------------------------- 8.1µL 
 d. Ultrapure H2O------------------------------------------------------------ 10.8µL 
3. Distribute 7µL of the M1 and P2 master mix to each of the wells (Figure D.1). 
4. Add 5µL of your mRNA sample. 
5. Seal plate, cover with foil, vortex, and centrifuge at 2000 rpm for 2 minutes. 
6. Run the plates by using a real-time PCR machine (ABI 7900HT). 
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a. Use the Sequence Detection System (SDS) program template with the
following settings: initial denaturing for 5 minutes at 48ºC, followed by 20 seconds at 
95ºC, and then 45 amplification cycles using the following parameters; reverse 
transcriptase inactivation for 3 seconds at 95ºC and polymerase activation for 30 seconds 
at 56ºC. 
7. Analyze results using the Sequence Detection System, Version 2.4.1 (SDS 2.4)
software. 
Figure D.1. Distribute 7µL of the M1 and P2 master mix to each of the wells. 
E) Infect cell culture line from urine of PaBV positive shedding
birds 
This process consisted of three parts: 1) Collection of urine from two PaBV 
positive shedding African Grey parrots and one PaBV negative shedding African Grey 
parrot; 2) Detection of PaBV in urine using one-step taqman RT-PCR for viral P-protein 
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mRNA; 3) Infecting cell culture lines with the urine of the African Grey parrots. NOTE: 
We detecting the virus in cell culture using indirect immunocytochemistry by looking 
for viral N-protein and one-step taqman RT-PCR by looking for viral P-protein mRNA. 
Part I 
1. The three African grey parrots were sedated and given 10mL of fluids for the
increase of urine production. (10 minute waiting period) 
2. Each bird was carried in flight position for a better visualization of the cloacal
vent. 
3. A microtube containing a window was placed inside the cloacal vent; window
was positioned towards the urodeum using visual confirmation. 
4. Urine flowed from the urogenital papilla into the microtube and then suctioned
with capillary tubes. 
5. The urine was filtered using an Acrodisc syringe filter with Nylon membrane,
diameter 13mm, pore size 0.45 micron. 
6. Prior to infecting DEF cells, a portion of urine was tested with one-step taqman
RT-PCR for the detection of PaBV P RNA to confirm viral presence. 
Part II 
1. Prepare cell culture cabinet (BSL II cabinet) with an electronic pipettor, complete
media solution (DMEM media that contains 10% fetal bovine serum and 1% 
penicillin streptomycin) (Life technologies Co.) and a discard beaker containing 
10% bleach solution. NOTE: DMEM media needs to be at room temperature 
prior to use to prevent rupturing of cells. 
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2. Insert 1 cryogenic vial containing 1mL of clean DEF cells into a clean latex 
glove and tie a knot to minimize the amount of water exposure.  
3. Quick thaw the vial in a 37ºC water bath by swirling the vial in water just until 
thawed to ensure a higher proportion of cells survive. This will take about 2-3 
minutes. 
4. Remove vial from clean latex glove and spray vial with 10% bleach before 
placing it in cell culture cabinet. 
5. Add 10mL of complete media solution into a 15mL conical tube. 
6. Pour cryogenic vial of clean DEF cells into the 15mL conical tube with 10mL 
complete media solution. 
7. Solution will then be centrifuged at 1000 rpm and 10ºC for 10 minutes in an 
Allegra X-15 centrifuge. NOTE: Make sure to balance centrifuge with another 
15mL conical tube containing 11mL tap water. 
8. Remove the supernatant from the conical tube and discard in beaker with 10% 
bleach. 
9. To resuspend the pelleted cells, add 5mL of complete media solution and mix 
slowly with the electronic pipettor.  
14. Finally, add the 5mL of resuspended cells into one 25mL flasks and incubate in a 
clean cell culture incubator at 37ºC and 5% CO2. 
15. Check cells daily for about 3-4 days or until cell confluence is 80-90%. When 
25mL flask has 80-90% cell confluence, the cells will be transferred into a 24 
well plate.  
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Part III 
1. To begin separating cells from the 25mL flask into a 24 well plate, the 5 mL of
complete media are removed and discarded in a beaker with 10% bleach solution. 
2. Cells are then detached from the 25mL flask floor by using 0.25% trypsin-
EDTA. 
a. Use 1.5mL of 0.25% trypsin-EDTA to wash (by swirling trypsin on
flask floor) for 2 seconds. 
b. Immediately after wash remove the 1.5mL of 0.25% trypsin-EDTA
and discard in beaker with 10% bleach solution. NOTE: This step 
removes any excess complete media and begins the enzymatic 
digestion of trypsin. 
3. 0.5mL of trypsin is then added and swirled until the complete flask floor is
covered. 
4. The 25mL flask is then placed in the clean cell culture incubator for 2 minutes or
until cells are seen detached by using a cell culture microscope. 
5. To stop trypsin’s enzymatic digestion, add 12mL of complete media solution and
gently agitate flask with your hand to loosen any adhered cells. 
6. Add the 0.5mL of complete media with cells to each of the 24 wells in a plate
and incubate in clean cell culture incubator until it reaches 50-60% cell 
confluence (approximately 2-3 days). 
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Part IV 
To infect DEF cells with the urine of PaBV positive shedding African grey parrots. 
Urine was divided into 2 categories: 1) Diluted urine 2) Concentrated urine 
(containing urates) and both were tested with one-step taqman RT-PCR for the 
detection of PaBV P mRNA in order to confirm viral presence. By the time the clean 
cell culture 24 well plate reached 50-60% cell confluence the diluted urine was 
filtered and treated with anti-fungal and anti-bacterial to prevent contamination. 
1. The 24 well plate containing duck embryonic fibroblast cells was infected with
0.1 mL of filtered urine and allowed to incubate for 18 days (Figure D.2). 
Infecting Cells in 24 Well plate 
 In columns 1, add 1.0 mL of 2% FBS media to each well
 In column 2, add 1.0 mL of post-filtered urine from PaBV negative
shedding bird. 
 In column 3, add 1.0 mL of post-filtered urine from PaBV positive
shedding bird-1. 
 In column 4, add 1.0 mL of post-filtered urine from PaBV positive
shedding bird-2. 
 In columns 5, add 1.0 mL of 10-1 PaBV-4 to each well
 In columns 6, add 1.0 mL of 10-2 PaBV-4 to each well
2. For our positive controls we used dilutions of duck embryonic fibroblast cells
infected with PaBV-4. 
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PaBV Infected Cell Dilutions 
Use 2% FBS media for this part 
1. Quick thaw 1 vial of PaBV4 infected DEF cells in 37
o
C while swirling,
then spray exterior with 70% alcohol. 
2. Dilutions
i. 10
-1
 = Add 0.4 mL of thawed virus into 3.6 mL 2% FBS
media 
ii. 10
-2
 = Add 1.5 mL of 10
-1
 into 13.5 mL 2% FBS media
3. Each well in the 24 well plate had a sample removed every 2-3 days. With these
samples we performed one-step taqman qRT-PCR in order to detect the presence 
of PaBV P mRNA. (Process repeated 6-9 times) 
1. The 1 mL of complete media in each of the 24 wells are removed and
discarded in a beaker with 10% bleach solution. 
2. Cells are detached from the 24 well plate floor by using 0.25% trypsin-
EDTA. 
a. Use 0.5mL of 0.25% trypsin-EDTA to wash (by swirling trypsin
on flask floor) for 2 seconds. 
b. Immediately after wash remove the 1.5mL of 0.25% trypsin-
EDTA and discard in beaker with 10% bleach solution. NOTE: 
This step removes any excess complete media and begins the 
enzymatic digestion of trypsin. 
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3. 0.2mL of trypsin then is added and swirled until the complete well floor
is covered. 
4. The plate is then placed in the clean cell culture incubator for 2 minutes
or until cells are seen detached by using a cell culture microscope. 
5. To stop trypsin’s enzymatic digestion, add 1mL of complete media
solution and gently agitate plate with your hand to loosen any adhered 
cells. 
6. Remove 0.5mL of complete media with cells and insert into a cryo-vial
and store in -80ºC for the detection of PaBV P mRNA by one-step 
taqman qRT-PCR. 
7. Finally, add 0.5ml of clean media to each 24 well and incubate in “dirty”
cell culture incubator until 90-100% cell confluence (approximately 2-3 
days). 
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Figure D.2. Twenty four well plate containing duck embryonic fibroblast cells  
 was infected with 0.1mL of filtered urine. 
